Australian Broker Call
Produced and copyrighted by
at www.fnarena.com
August 20, 2026
Access Broker Call Report Archives here
COMPANIES DISCUSSED IN THIS ISSUE
Click on symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1).
Last Updated: 05:25 PM
Your daily news report on the latest recommendation, valuation, forecast and opinion changes.
This report includes concise but limited reviews of research recently published by Stockbrokers, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end.
For more info about the different terms used by stockbrokers, as well as the different methodologies behind similar sounding ratings, download our guide HERE
Today's Upgrades and Downgrades
| AVH - | Avita Medical | Downgrade to Sell from Hold | Morgans |
| BRG - | Breville Group | Downgrade to Accumulate from Buy | Morgans |
| COS - | Cosol | Downgrade to Hold from Buy | Ord Minnett |
| EVN - | Evolution Mining | Downgrade to Hold from Buy | Morgans |
| SGP - | Stockland | Upgrade to Buy from Neutral | UBS |
| TPW - | Temple & Webster | Downgrade to Equal-weight from Overweight | Morgan Stanley |
Overnight Price: $1.64
Morgans rates AEL as Buy (1) -
Morgans maintains a Buy rating for Amplitude Energy with its target price decreased to $2.90 from $3.05 following solid FY26 underlying earnings of $45m, up from $9m a year earlier.
The analyst highlights that, although market sentiment toward exploration remains depressed, management plans to target cash returns to shareholders once East Coast Supply Project growth is delivered.
Commentary states management continues to navigate domestic gas uncertainties while positioning the company to generate over $200m in EBITDA annually from FY27.
The valuation is supported by a solid earnings platform, a capable balance sheet, and a focus on maximising free cash flow generation.
Target price is $2.90 Current Price is $1.64 Difference: $1.265
If AEL meets the Morgans target it will return approximately 77% (excluding dividends, fees and charges).
Current consensus price target is $2.59, suggesting upside of 51.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 18.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.6, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 9.7. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 0.00 cents and EPS of 25.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.7, implying annual growth of 40.3%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 6.9. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.09
Bell Potter rates ALC as Buy (1) -
Cost discipline and improving operating leverage were key positives from Alcidion's FY26 result, with EBITDA of $6.2m beating guidance of more than $5m and Bell Potter's $5.8m forecast. Underlying EBITDA rose 34% to $6.8m.
Staff costs fell to 53% of revenue from 65% in FY25, ARR climbed to $38.3m from $31.1m at December 2025 and the company finished debt free with $20.6m cash.
Contracted FY27 revenue stands at $44.9m, up $10.9m y/y. The analyst points out its forecast requires only $10.2m of additional revenue wins during FY27 versus $17.6m achieved in FY26.
The broker makes modest earnings downgrades but sees further contract opportunities across new geographies, expansion with existing UK and Australian customers and additional EPR awards. Buy retained with an unchanged $0.15 target.
Target price is $0.15 Current Price is $0.09 Difference: $0.059
If ALC meets the Bell Potter target it will return approximately 65% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.20 cents. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 0.30 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates APA as Buy (1) -
At first glance, Citi assesses a solid FY26 result by APA Group today, with strong free cash flow (FCF) and an expanded organic development pipeline.
The broker expects the pipeline, higher EBITDA margins and in-line FY27 guidance to support a positive share price reaction.
FY26 underlying earnings (EBITDA) of $2.18bn were broadly in line, while FCF per share of 84.4c beat consensus by 3.5%, the analysts highlight.
The broker also highlights a -12% decline in operating costs and expects the full benefit to support FY27 earnings and FCF.
As noted above, FY27 EBITDA guidance of $2.26bn–$2.34bn is in line with consensus, according to Citi.
The FY27-FY29 organic pipeline has expanded to $3.5bn, despite around $550m of organic capex spent in FY26, the analysts explain.
Buy rating. Target $11.10.
Target price is $11.10 Current Price is $10.10 Difference: $1
If APA meets the Citi target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $9.44, suggesting downside of -7.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 58.00 cents and EPS of 16.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.3, implying annual growth of 139.5%. Current consensus DPS estimate is 58.0, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 55.7. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 59.00 cents and EPS of 20.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.5, implying annual growth of 28.4%. Current consensus DPS estimate is 59.0, implying a prospective dividend yield of 5.8%. Current consensus EPS estimate suggests the PER is 43.4. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates APA as Outperform (1) -
First Impressions: APA Group's FY26 underlying NPAT rose 10% and beat Macquarie and consensus, while EBITDA was in line with the broker and towards the upper end of guidance.
Macquarie highlights 6% revenue growth across the East Coast Gas business and stronger cost reductions, with $80m of savings exceeding the $50m target and another $20m expected in FY27.
FY27 EBITDA guidance of $2.26bn-$2.34bn is broadly in line with expectations, while the three-year capex program has increased to $3.5bn as APA progresses its pipeline of gas infrastructure projects and explores data centre opportunities.
Macquarie retains Outperform, viewing the valuation as attractive and the circa 5.9% yield as sustainable. Target $10.41.
Target price is $10.41 Current Price is $10.10 Difference: $0.31
If APA meets the Macquarie target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $9.44, suggesting downside of -7.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 58.00 cents and EPS of 18.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.3, implying annual growth of 139.5%. Current consensus DPS estimate is 58.0, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 55.7. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 59.00 cents and EPS of 24.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.5, implying annual growth of 28.4%. Current consensus DPS estimate is 59.0, implying a prospective dividend yield of 5.8%. Current consensus EPS estimate suggests the PER is 43.4. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates APA as Sell (5) -
UBS maintains a Sell rating for APA Group with an unchanged price target of $8.00 following an in-line FY26 result featuring improved underlying EBITDA of $2,183m and disciplined cost management.
Underlying NPAT of $247m missed UBS estimates due to higher depreciation and amortisation alongside elevated interest costs.
Management guided FY27 EBITDA to $2,260m-$2,340m and lifted organic growth capital expenditure to $3.5bn across FY27-FY29, while highlighting growing contracting pressures across parts of the East Coast grid.
The stock trades on a net debt to EBITDA of 6.1x with forecast dividends per share guided higher to 59.0c.
Target price is $8.00 Current Price is $10.10 Difference: minus $2.1 (current price is over target).
If APA meets the UBS target it will return approximately minus 21% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $9.44, suggesting downside of -7.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 58.00 cents and EPS of 21.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.3, implying annual growth of 139.5%. Current consensus DPS estimate is 58.0, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 55.7. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 59.00 cents and EPS of 26.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.5, implying annual growth of 28.4%. Current consensus DPS estimate is 59.0, implying a prospective dividend yield of 5.8%. Current consensus EPS estimate suggests the PER is 43.4. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
AVH AVITA MEDICAL INC
Pharmaceuticals & Biotech/Lifesciences
More Research Tools In Stock Analysis - click HERE
Overnight Price: $2.71
Morgans rates AVH as Downgrade to Sell from Hold (5) -
Morgans downgrades Avita Medical to Sell from Hold with its target price increased to $2.20 from $1.35 following a second-quarter report that delivered record revenue, a second FY26 guidance upgrade, and net cash burn nearly halved quarter-on-quarter.
The analyst highlights that PermeaDerm-I hit its primary endpoint by demonstrating healing comparable to allograft at a significantly lower cost, providing a useful health economics indicator for cross-selling Cohealyx and Recell.
The broker upgrades FY26 revenue growth assumptions and factors in minor operating expense reductions following the cost reset.
Management guides towards fourth-quarter cash flow breakeven while navigating elevated debt obligations and skinny cash reserves.
The valuation is supported by a discounted cash flow methodology alongside positive commercial recovery metrics, the report explains.
Target price is $2.20 Current Price is $2.71 Difference: minus $0.51 (current price is over target).
If AVH meets the Morgans target it will return approximately minus 19% (excluding dividends, fees and charges - negative figures indicate an expected loss).
The company's fiscal year ends in December.
Forecast for FY26:
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 26.25 cents. |
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 3.94 cents. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.65
Bell Potter rates AYA as Buy (1) -
Artrya enters FY27 with its foundation Salix customer fully onboarded and around $74m in cash, leaving the company well-funded through to Bell Potter's expected breakeven in FY28.
The FY26 operating loss of around -$27.6m was largely as expected and reflects the platform's early commercialisation phase, while net operating cash outflow increased to around -$18m from -$14.3m.
Early customer experience is encouraging, with Tanner Health reporting CCTA interpretation time reductions of around -50%-80%, while NGHS is now onboarded and Cone Health is expected to complete onboarding this quarter.
FY27 is expected to show the repeatability of Salix's workflow benefits and potentially deliver conversion of at least one SAPPHIRE study partner, with initial study data potentially available in 2H calendar 2027.
Target raised to $6.75 from $6.10.
Target price is $6.75 Current Price is $4.65 Difference: $2.1
If AYA meets the Bell Potter target it will return approximately 45% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 10.30 cents. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 1.60 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $6.01
UBS rates BGA as Neutral (3) -
First take: UBS maintains a Neutral rating for Bega Cheese with an unchanged price target of $6.10 following an FY26 financial result featuring revenue and underlying EBITDA at the top end of guidance.
Revenue reached $3,775m alongside an underlying EBITDA increase of 12% to $226m, while net debt closed at $152m representing a conservative 0.8x leverage.
Management guides FY27 normalised EBITDA to $240m-$245m and reaffirms medium-term growth targets, including >$250m for FY28 and >$310m for FY31.
The broker's estimates indicate continued operational momentum driven by footprint rationalisation and cost management initiatives such as warehouse automation.
Target price is $6.10 Current Price is $6.01 Difference: $0.09
If BGA meets the UBS target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $6.54, suggesting downside of -1.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 16.00 cents and EPS of 23.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.1, implying annual growth of N/A. Current consensus DPS estimate is 14.4, implying a prospective dividend yield of 2.2%. Current consensus EPS estimate suggests the PER is 28.8. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 18.00 cents and EPS of 26.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.6, implying annual growth of 10.8%. Current consensus DPS estimate is 17.1, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 26.0. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $63.71
UBS rates BHP as Neutral (3) -
UBS has taken its time to properly assess BHP Group's FY26 release. All in all, the conclusion is the Big Aussie released a strong FY26 result, with underlying EBITDA in line and cash generation and returns better than anticipated.
That consensus-beating final dividend proved smack in line with UBS's forecast.
Equally important, management at the miner remains confident it can deliver on its growth plans, particularly for the copper division.
Commentary concludes the risk/reward is now balanced with the shares trading at a premium to other diversified miners on the back of strong operational performance and discipline.
Neutral. Target $59. Current forecasts imply the peak in growth is in, with FY27 flat and negative growth for FY28.
Target price is $59.00 Current Price is $63.71 Difference: minus $4.71 (current price is over target).
If BHP meets the UBS target it will return approximately minus 7% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $61.05, suggesting downside of -7.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 189.56 cents and EPS of 377.66 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 393.5, implying annual growth of N/A. Current consensus DPS estimate is 215.5, implying a prospective dividend yield of 3.3%. Current consensus EPS estimate suggests the PER is 16.7. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 177.89 cents and EPS of 355.79 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 376.5, implying annual growth of -4.3%. Current consensus DPS estimate is 219.9, implying a prospective dividend yield of 3.3%. Current consensus EPS estimate suggests the PER is 17.5. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
BRG BREVILLE GROUP LIMITED
Household & Personal Products
More Research Tools In Stock Analysis - click HERE
Overnight Price: $31.72
Citi rates BRG as Buy (1) -
Following Breville Group's FY26 results, Citi raises its target to $40.80 from $39.65 and maintains its Buy rating.
The key takeaway from the conference call is that FY27 is in a better position to grow earnings versus FY26. Lower tariffs from the new manufacturing base should support margins, while young markets are highlighted by Citi as scaling.
Notably, the premium consumer remains resilient, which is the major factor against a backdrop of ongoing risks from tariff volatility to the Middle East war.
Following today's FY26 result by Breville Group, Citi's first impression is that its structural growth thesis remains intact despite continued pressure on earnings conversion and margins.
FY26 earnings (EBIT) of $207m were in line with consensus, while second-half gross margin improved to 36.8% from 35.4% in H1 and net cash increased to $104.4m from $48.5m, the analysts highlight.
Citi sees espresso, geographic expansion and solutions/services supporting growth, while M&A provides further upside given the strong balance sheet.
As per usual practice, no FY27 guidance was provided.
Target price is $40.80 Current Price is $31.72 Difference: $9.08
If BRG meets the Citi target it will return approximately 29% (excluding dividends, fees and charges).
Current consensus price target is $37.74, suggesting upside of 17.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 40.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.5, implying annual growth of N/A. Current consensus DPS estimate is 41.3, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 30.5. |
Forecast for FY28:
Current consensus EPS estimate is 118.8, implying annual growth of 12.6%. Current consensus DPS estimate is 46.2, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 27.1. |
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates BRG as Outperform (1) -
Breville Group continued to deliver 10% Global Product constant currency revenue growth in FY26, Macquarie notes, while managing margins and diversifying product manufacturing.
Tariff refunds were largely offset by a supply-chain provision. The net benefit was more than offset by other cost headwinds.
China, Korea, Mexico and Middle East collectively grew at 74% year on year. China, in the first full year of direct operation, delivered 7.1x the revenue of previous distributor, Macquarie notes, and Middle East delivered 6.6x.
Coffee growth, new market entry and new product development continue to drive attractive revenue growth and margins have been well managed, in the broker's view. Outperform and $37.10 target retained.
Target price is $37.10 Current Price is $31.72 Difference: $5.38
If BRG meets the Macquarie target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $37.74, suggesting upside of 17.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 42.50 cents and EPS of 106.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.5, implying annual growth of N/A. Current consensus DPS estimate is 41.3, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 30.5. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 48.90 cents and EPS of 122.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 118.8, implying annual growth of 12.6%. Current consensus DPS estimate is 46.2, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 27.1. |
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates BRG as Overweight (1) -
Breville Group posted 6.7% FY26 revenue growth and 2% in 2H26 at headline, implying a half-on-half growth slowdown after 10%-plus in FY25 and 1H26, Morgan Stanley notes, but in constant currency, group sales rose 9% and Global Product 9.7% in FY26.
Breville posted a record gross margin of 36% in FY26, the broker highlights, with a record 36.8% in 2H26 despite marked uncertainty from tariffs, raw material price inflation, manufacturing diversification, and historically weaker second half seasonality.
The company's headwinds are transitory (FX, COGS volatility, and freight), the broker states, while adding its tailwinds are structural (category growth, competitive position, distribution optionality, faster new product development), and record margins have come with further efficiency gains.
Despite the stock's -4% drop on release in response to transitory headwinds, Morgan Stanley sees the structural story as completely intact. Target falls to $38.00 from $38.20, Overweight retained. Industry View: In-Line.
Target price is $38.00 Current Price is $31.72 Difference: $6.28
If BRG meets the Morgan Stanley target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $37.74, suggesting upside of 17.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 42.70 cents and EPS of 107.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.5, implying annual growth of N/A. Current consensus DPS estimate is 41.3, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 30.5. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 48.60 cents and EPS of 121.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 118.8, implying annual growth of 12.6%. Current consensus DPS estimate is 46.2, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 27.1. |
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates BRG as Downgrade to Accumulate from Buy (2) -
Morgans moves its recommendation for Breville Group to Accumulate from Buy with its target price decreased to $35.55 from $36.75 following an FY26 EBIT result of $207m representing 1% growth year-on-year, in line with guidance.
The analyst highlights revenue growth was slightly below expectations at approximately 2% due to foreign exchange headwinds in the second half, though constant currency growth remained solid at 10%.
The broker adjusts FY27 to FY29 EPS forecasts down by -2.0% to -4.2% while factoring in a robust outlook supported by new market expansion and strong new product development pipelines.
Commentary suggests the business maintains a commanding net cash position of $104.4m alongside an increased full-year dividend of 38cps.
The valuation is derived from a blended discounted cash flow and EV to EBIT methodology.
Target price is $35.55 Current Price is $31.72 Difference: $3.83
If BRG meets the Morgans target it will return approximately 12% (excluding dividends, fees and charges).
Current consensus price target is $37.74, suggesting upside of 17.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 41.90 cents and EPS of 104.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.5, implying annual growth of N/A. Current consensus DPS estimate is 41.3, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 30.5. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 46.50 cents and EPS of 116.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 118.8, implying annual growth of 12.6%. Current consensus DPS estimate is 46.2, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 27.1. |
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates BRG as Buy (1) -
Ord Minnett maintains Buy and raises its target for Breville Group to $38.00 from $37.20 after FY26 results broadly matched expectations.
NPAT rose 1.7% to $138.1m and constant-currency revenue increased 9.7%, although EBIT margin contracted to 11.4% from 12.1%.
The broker expects margins to recover as manufacturing diversification costs decline, supported by new products and geographic expansion.
Forecasts were updated for the result, with FY27 NPAT estimated at $152.3m; near-term currency headwinds remain the primary risk, the report concludes.
Target price is $38.00 Current Price is $31.72 Difference: $6.28
If BRG meets the Ord Minnett target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $37.74, suggesting upside of 17.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 39.00 cents and EPS of 105.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.5, implying annual growth of N/A. Current consensus DPS estimate is 41.3, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 30.5. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 42.00 cents and EPS of 118.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 118.8, implying annual growth of 12.6%. Current consensus DPS estimate is 46.2, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 27.1. |
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates BRG as Buy (1) -
On further inspection, the target price is raised to $37 from $36 with UBS highlighting EBIT growth is expected to be double-digit in the long term, from FY27 onwards.
The analyst flags upside to near-term gross margin due to a stronger 2H26 result, as well as lower tariffs and Middle East uncertainty.
Investment in advertising and new products is expected to continue to boost revenue growth.
EPS forecasts are tweaked lower for FY28 by -7%. Retain Buy rating.
First Take: Breville Group delivered FY26 EBIT in line with UBS and consensus, as weaker revenue growth was offset by better gross and EBIT margins, while strong cash flow helped the company finish with $104m net cash.
No FY27 guidance was provided, although the analyst sees company-specific tailwinds from new products, geographic expansion and store-in-store growth, balanced against tariff and cost uncertainty.
Target $36. Buy.
Target price is $37.00 Current Price is $31.72 Difference: $5.28
If BRG meets the UBS target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $37.74, suggesting upside of 17.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 41.00 cents and EPS of 104.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.5, implying annual growth of N/A. Current consensus DPS estimate is 41.3, implying a prospective dividend yield of 1.3%. Current consensus EPS estimate suggests the PER is 30.5. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 45.00 cents and EPS of 116.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 118.8, implying annual growth of 12.6%. Current consensus DPS estimate is 46.2, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 27.1. |
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates BWP as Neutral (3) -
BWP Trust's FY26 dividend of 19.41cpu is in line with guidance and consensus, up 4.1% on FY25. Funds from operations of 19.29cpu were in line with the 90%-100% payout ratio guidance range.
FY27 dividend guidance of 20cpu is above consensus. Profit on the sale of properties offsets lost rent resulting from development and divestments, Macquarie notes.
The dividend payout guidance is at 104% of funds from operations, implying FFO below consensus. BWP Trust is one of the most defensive REITs, Macquarie suggests, with dry powder to deploy accretively.
Target falls to $3.70 from $3.90, Neutral retained.
Target price is $3.70 Current Price is $3.80 Difference: minus $0.1 (current price is over target).
If BWP meets the Macquarie target it will return approximately minus 3% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $3.95, suggesting upside of 6.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 20.00 cents and EPS of 19.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.9, implying annual growth of N/A. Current consensus DPS estimate is 20.0, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 18.7. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 20.20 cents and EPS of 20.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 20.8, implying annual growth of 4.5%. Current consensus DPS estimate is 20.6, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 17.9. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates BWP as Equal-weight (3) -
BWP Trust reported FY26 funds from operations of 19.29cps, broadly in line with Morgan Stanley. The REIT has guided to a FY27 dividend of 20cps, at a payout ratio of 104%, implying that FFO would be 19.23cps, so essentially a flat earnings outlook.
BWP's strong balance sheet gives it plenty of options, the broker suggests, as exemplified by the acquisition of Sunbury. Morgan Stanley did expect the FY27 dividend to be fully covered by FFO, given a suite of projects due to be completed between September and March.
Gearing is fine at 18.5%, Morgan Stanley notes, leaving plenty of room to fund the $120m of committed capex. Equal-weight and $4.20 target retained. Industry view: In Line.
Target price is $4.20 Current Price is $3.80 Difference: $0.4
If BWP meets the Morgan Stanley target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $3.95, suggesting upside of 6.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 20.00 cents and EPS of 20.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.9, implying annual growth of N/A. Current consensus DPS estimate is 20.0, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 18.7. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 21.00 cents and EPS of 21.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 20.8, implying annual growth of 4.5%. Current consensus DPS estimate is 20.6, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 17.9. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $19.47
Citi rates BXB as Buy (1) -
Despite a mixed FY26 result and softer FY27 outlook for Brambles, with supply constraints creating a larger-than-expected near-term earnings drag, Citi, in an early assessment, remains upbeat on Brambles.
Constant-currency earnings (EBIT) rose 4%, despite a roughly -$90m repair shortage impact, while FY27 EBIT growth guidance of 2%-6% is below the consensus estimate of 6%, the analyst observes.
A -$95m-$115m repair shortage headwind is anticipated in 1H27 before a $55m-$65m benefit in 2H27, supporting a second-half recovery.
FY27 free cash flow (FCF) guidance of $800m-$950m is also expected to support further buybacks, while three-year margin targets remain on track, the broker highlights.
Buy rating. Target $22.80.
Target price is $22.80 Current Price is $19.47 Difference: $3.33
If BXB meets the Citi target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $21.32, suggesting upside of 13.4% (ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 95.3, implying annual growth of N/A. Current consensus DPS estimate is 58.8, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 19.7. |
Forecast for FY27:
Current consensus EPS estimate is 103.8, implying annual growth of 8.9%. Current consensus DPS estimate is 62.8, implying a prospective dividend yield of 3.3%. Current consensus EPS estimate suggests the PER is 18.1. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates BXB as Neutral (3) -
First Impressions: Brambles' FY26 result was slightly ahead of expectations, with sales rising 6% y/y, and underlying EBIT increasing 9% y/y, ahead of Macquarie and consensus.
The Americas was the key weakness, with US repair constraints costing around -US$90m in FY26 and expected to remain a -US$35m-US$55m EBIT headwind in FY27, leaving the earnings recovery weighted towards 2H27.
EMEA remained solid and APAC EBIT rose 14%, while free cash flow of US$1.05bn beat consensus and supported a 16% increase in dividends and the ongoing buyback.
Macquarie retains Neutral, noting FY27 performance hinges on resolving US repair constraints while underlying market growth remains soft. Target $18.60.
Target price is $18.60 Current Price is $19.47 Difference: minus $0.87 (current price is over target).
If BXB meets the Macquarie target it will return approximately minus 4% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $21.32, suggesting upside of 13.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 61.97 cents and EPS of 94.63 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 95.3, implying annual growth of N/A. Current consensus DPS estimate is 58.8, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 19.7. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 62.70 cents and EPS of 105.57 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 103.8, implying annual growth of 8.9%. Current consensus DPS estimate is 62.8, implying a prospective dividend yield of 3.3%. Current consensus EPS estimate suggests the PER is 18.1. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $43.48
UBS rates CDA as Neutral (3) -
First take: UBS maintains a Neutral rating for Codan with an unchanged price target of $42.50 following a strong FY26 result where top-line revenue and EBIT came in 3% and 4% ahead of consensus respectively.
The company reported a 69% increase in net profit after tax to $175m, driven by robust communications segment performance and accelerating earnings momentum within the metal detection division.
Management points to communications revenue growth of 20% into FY27 alongside strong order momentum, while operating cash flow surged 70% to $249m.
The broker's estimates reflect ongoing positive momentum across both core operating segments heading into FY27.
Target price is $42.50 Current Price is $43.48 Difference: minus $0.98 (current price is over target).
If CDA meets the UBS target it will return approximately minus 2% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $43.08, suggesting downside of -11.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 46.00 cents and EPS of 93.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 90.9, implying annual growth of 59.2%. Current consensus DPS estimate is 42.1, implying a prospective dividend yield of 0.9%. Current consensus EPS estimate suggests the PER is 53.8. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 51.00 cents and EPS of 103.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 103.8, implying annual growth of 14.2%. Current consensus DPS estimate is 49.4, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 47.1. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CGF CHALLENGER LIMITED
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $9.80
Ord Minnett rates CGF as Buy (1) -
Ord Minnett maintains Challenger on Buy with a $11.70 target (was $11 previously) after FY26 normalised NPAT rose 3% to $468m, ahead of consensus.
Life sales increased 12%, including 19% annuity growth, while Challenger expanded its buyback to $450m and reported $1.1bn of surplus capital.
The broker believes the buyback and a modest 14 times consensus earnings multiple support valuation, although the new core EPS measure excludes around one-third of forecast FY27 profit and may confuse investors.
FY27-FY29 forecasts were reduced by circa -3% annually because the Fidante transaction is expected to be more dilutive than previously assumed; sustaining annuity growth is considered the principal risk.
Target price is $11.70 Current Price is $9.80 Difference: $1.9
If CGF meets the Ord Minnett target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $10.66, suggesting upside of 8.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 34.00 cents and EPS of 68.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 69.3, implying annual growth of -15.6%. Current consensus DPS estimate is 34.2, implying a prospective dividend yield of 3.5%. Current consensus EPS estimate suggests the PER is 14.2. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 37.00 cents and EPS of 73.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 74.0, implying annual growth of 6.8%. Current consensus DPS estimate is 38.3, implying a prospective dividend yield of 3.9%. Current consensus EPS estimate suggests the PER is 13.3. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $137.30
Morgans rates COH as Hold (3) -
Morgans maintains a Hold rating for Cochlear with its target price increased to $138.42 from $107.17 following a mixed FY26 result that delivered underlying net profit after tax of $322m, beating consensus by 6% on broadly in-line revenue of $2,348m.
The analyst highlights that while the result benefited from a stronger second half and solid Nexa platform adoption across more than 95% of developed-market implants, gross profit margins contracted by -300 basis points to 71% due to modest developed-market demand, increased low-tier sales in China, reduced production, and foreign exchange pressures.
The broker's estimates adjust FY27 to FY28 per-share earnings down by up to -2.3% on lower cochlear implant revenue and tighter margins.
Management targets FY27 constant currency sales growth in the low-single digits alongside underlying net profit after tax guidance of $330m to $350m.
The valuation is supported by a blended discounted cash flow, price-to-earnings, and enterprise value to EBITDA framework.
Target price is $138.42 Current Price is $137.30 Difference: $1.12
If COH meets the Morgans target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $136.87, suggesting upside of 0.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 355.00 cents and EPS of 517.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 525.8, implying annual growth of 133.5%. Current consensus DPS estimate is 373.2, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 26.0. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 398.00 cents and EPS of 584.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 582.2, implying annual growth of 10.7%. Current consensus DPS estimate is 394.5, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 23.5. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates COH as Neutral (3) -
A lengthy series of questions to Cochlear management points to UBS seeing Cochlear's FY27 outlook as relatively conservative.
The key debate on the outlook is centred on whether improving implantation rates, stronger Nexa uptake and better cost control can drive growth above current expectations.
The broker is focused on US payer frictions, European funding and access constraints, China market dynamics and whether Cochlear can rebuild share in key markets such as Germany.
UBS also highlights execution risk around the cloud program, inventory movements and the path back towards higher margins, while monitoring the competitive implications of totally implantable cochlear implants. Neutral with a $150.00 target.
Target price is $150.00 Current Price is $137.30 Difference: $12.7
If COH meets the UBS target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $136.87, suggesting upside of 0.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 366.00 cents and EPS of 519.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 525.8, implying annual growth of 133.5%. Current consensus DPS estimate is 373.2, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 26.0. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 402.00 cents and EPS of 569.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 582.2, implying annual growth of 10.7%. Current consensus DPS estimate is 394.5, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 23.5. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.20
Ord Minnett rates COS as Downgrade to Hold from Buy (3) -
Ord Minnett downgrades Cosol to Hold from Buy and cuts its target to $0.20 from $0.31, down -35.5%, following a weaker-than-expected FY26 result and the departure of chief executive Scott McGowan.
Commentary explains revenue weakness and divisional margin compression drove normalised NPAT down to $3.3m, while impairments reflected subdued East Coast coal-sector demand.
Management's five-point turnaround plan targets sales growth, restored margins, AI revenue and expansion in transport and the Americas, the report notes.
Forecasts and valuation were rebased for the weaker result.
Target price is $0.20 Current Price is $0.20 Difference: $0.005
If COS meets the Ord Minnett target it will return approximately 3% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.30 cents. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 0.00 cents and EPS of 1.60 cents. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CSL CSL LIMITED
Pharmaceuticals & Biotech/Lifesciences
More Research Tools In Stock Analysis - click HERE
Overnight Price: $166.48
Morgan Stanley rates CSL as Overweight (1) -
In a follow up to Morgan Stanley's FY26 result analysis, the broker notes CSL Behring's revenue growth improved year on year in 2H26, supported by improved growth for Ig, a less significant decline for albumin, and strong hereditary angioedema (HAE) growth.
For Ig, Morgan Stanley estimates that CSL's market share increased for the six months to June 2026 relative to Grifols and Takeda. In addition, CSL has indicated that supply and demand are balanced for both plasma and Ig.
The broker sees the FY26 result and FY27 guidance as highlighting improvement within CSL Behring, the key driver of group earnings growth over the medium to longer term. Overweight and $172 target retained. Industry view: In Line.
Target price is $172.00 Current Price is $166.48 Difference: $5.52
If CSL meets the Morgan Stanley target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $162.32, suggesting downside of -5.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 487.02 cents and EPS of 958.01 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 939.2, implying annual growth of N/A. Current consensus DPS estimate is 465.0, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 18.2. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 498.69 cents and EPS of 1023.62 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 994.7, implying annual growth of 5.9%. Current consensus DPS estimate is 491.9, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 17.2. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates CSL as Buy (1) -
A lengthy series of questions to CSL management has UBS highlighting several key issues for Australia's largest biotech following FY26 results, centred on whether immunoglobulin market conditions, plasma collection costs and margin recovery can support a return to stronger earnings growth.
The broker is particularly focused on competitive dynamics in the US Ig market, progress rebuilding market share, the outlook for 340B, albumin pricing in China, and whether lower cost per litre and manufacturing efficiencies can drive further Behring margin improvement.
UBS also highlights uncertainty around Vifor's earnings reset, Seqirus vaccination trends, Horizon II economics and the timing of benefits from CSL's cost-out program. Buy with a $181.00 target.
Target price is $181.00 Current Price is $166.48 Difference: $14.52
If CSL meets the UBS target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $162.32, suggesting downside of -5.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 425.78 cents and EPS of 898.22 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 939.2, implying annual growth of N/A. Current consensus DPS estimate is 465.0, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 18.2. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 447.65 cents and EPS of 965.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 994.7, implying annual growth of 5.9%. Current consensus DPS estimate is 491.9, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 17.2. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CWY CLEANAWAY WASTE MANAGEMENT LIMITED
Industrial Sector Contractors & Engineers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $2.59
UBS rates CWY as Buy (1) -
First Read: UBS notes Cleanaway Waste Management's FY26 EBIT was in line with its forecast and consensus, with growth supported by Solid Waste Services and Contract Resources. Industrial Services outperformed expectations.
FY27 EBIT guidance of $500m-$530m was unchanged from the pre-announcement and broadly in line with consensus.
Growth is expected from collections, recovery in Oils & Technical Services and Health Services, and Contract Resources, partly offset by higher technology and Blueprint 2030 investment.
Investor attention looks set to remain on execution of EQT's $3.13 per share bid, with the latest closing price still around a -17% discount to the offer.
Buy. Target $3.05.
Target price is $3.05 Current Price is $2.59 Difference: $0.46
If CWY meets the UBS target it will return approximately 18% (excluding dividends, fees and charges).
Current consensus price target is $2.87, suggesting upside of 10.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 7.00 cents and EPS of 10.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.1, implying annual growth of 43.7%. Current consensus DPS estimate is 6.8, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 25.7. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 8.00 cents and EPS of 12.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.1, implying annual growth of 19.8%. Current consensus DPS estimate is 8.2, implying a prospective dividend yield of 3.2%. Current consensus EPS estimate suggests the PER is 21.5. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.77
UBS rates DGT as Buy (1) -
Ahead of DigiCo Infrastructure REIT's 2H26 results, UBS believes the investment case has evolved considerably following the sale of CHI1 and LAX1/LAX2, shifting the growth focus towards Australia and reducing pro forma gearing to around 19% from 39%.
The stronger balance sheet should allow the group to self-fund the SYD1 expansion to 88MW, while exploring further capacity at ADL1 and BNE3.
The analyst sees scope for additional contract wins to drive further re-rating.
Adjusting for the asset sales, the broker cuts FY27-FY29 EPS forecasts by -31%/-24%/-9%.
UBS retains Buy and lowers its target to $3.75 from $4.20.
Target price is $3.75 Current Price is $2.77 Difference: $0.98
If DGT meets the UBS target it will return approximately 35% (excluding dividends, fees and charges).
Current consensus price target is $3.46, suggesting upside of 24.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 12.00 cents and EPS of 9.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 11.6, implying annual growth of N/A. Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 4.3%. Current consensus EPS estimate suggests the PER is 24.1. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 19.00 cents and EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 14.6, implying annual growth of 25.9%. Current consensus DPS estimate is 17.3, implying a prospective dividend yield of 6.2%. Current consensus EPS estimate suggests the PER is 19.1. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $7.45
Macquarie rates DOW as Outperform (1) -
First Impressions: Downer EDI's FY26 underlying NPATA was in line with Macquarie and within guidance, while operating cash flow of $503m was ahead of the broker's $487m forecast.
Transport Services and Energy & Utilities delivered EBITA growth of 7% and 20%, respectively, although pro forma group revenue declined -5% and Facilities earnings fell -5%.
Management expects revenue, margins and earnings to grow in FY27, but the analyst flags a larger-than-usual 2H weighting as contract awards and secured Defence and Water work ramp up.
1H27 revenue, earnings and margins expected to decline y/y. Macquarie forecasts FY27 NPATA growth of 7% to $326m and retains Outperform, seeing further contract opportunities supporting acceleration towards the group's 4%-5% long-term revenue growth target.
Target price is $8.90 Current Price is $7.45 Difference: $1.45
If DOW meets the Macquarie target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $8.58, suggesting upside of 28.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 29.30 cents and EPS of 44.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 44.4, implying annual growth of 117.9%. Current consensus DPS estimate is 29.2, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 15.0. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 31.50 cents and EPS of 48.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 47.6, implying annual growth of 7.2%. Current consensus DPS estimate is 31.8, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.0. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates DOW as Neutral (3) -
First Read: UBS notes Downer EDI's FY26 EBITA was in line with its forecast and consensus, as stronger margins offset weaker revenue.
Energy & Utilities outperformed expectations on energy transition activity and improved project execution, while Transport benefited from better execution and stabilisation in Australian Road Services, partly offset by weaker Facilities earnings.
FY27 guidance points to revenue, earnings and margin growth broadly consistent with forecasts, although the analyst highlights a larger than usual 2H weighting due to contract award timing and the ramp-up of secured work.
This implies mid-single-digit downgrades to 1H27 revenue and EBITA forecasts. The broker notes management remains confident in its FY30 ambitions for 4%-5% revenue CAGR and an EBITA margin approaching 6%.
Neutral. Target $8.
Target price is $8.00 Current Price is $7.45 Difference: $0.55
If DOW meets the UBS target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $8.58, suggesting upside of 28.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 29.00 cents and EPS of 44.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 44.4, implying annual growth of 117.9%. Current consensus DPS estimate is 29.2, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 15.0. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 32.00 cents and EPS of 47.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 47.6, implying annual growth of 7.2%. Current consensus DPS estimate is 31.8, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 14.0. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.44
Ord Minnett rates DRR as Accumulate (2) -
Ord Minnett maintains Deterra Royalties on Accumulate and raises its target to $4.90 from $4.80 after an in-line FY26 result.
Revenue declined -8% to $242m, but Mining Area C revenue increased 7% and reported NPAT rose 5% to $164m.
Commentary suggests Thacker Pass remains the major catalyst, with full production of 40,000tpa expected in 2028, while acquisitions could add another growth leg.
FY27-FY29 earnings forecasts are relatively unchanged.
Target price is $4.90 Current Price is $4.44 Difference: $0.46
If DRR meets the Ord Minnett target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $4.60, suggesting upside of 3.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 19.00 cents and EPS of 26.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 27.5, implying annual growth of -11.4%. Current consensus DPS estimate is 21.1, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 22.00 cents and EPS of 29.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 29.3, implying annual growth of 6.5%. Current consensus DPS estimate is 22.5, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 15.2. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates DXS as Neutral (3) -
First Take: Dexus delivered FY26 AFFO of 45.0cps, slightly ahead of Citi at 44.4cps and consensus.
FY27 guidance of 37.5c-39.5cps was better than the market had feared.
The analyst stresses the resilience across the core portfolio, with office occupancy rising to 95.7%, leasing volumes up 61% and industrial like-for-like income growth accelerating to 8.3%, while gearing remains comfortable at 33.4%.
FY26 result and guidance are expected to support the shares, although uncertainty remains around APAC litigation and the strategic review of $7.3bn of infrastructure FUM, which is expected to make a materially lower earnings contribution in FY27.
Balance sheet flexibility and continued buybacks are viewed as supportive given the stock is trading at a circa -35% discount to NTA.
Neutral. Target $6.50.
Target price is $6.50 Current Price is $5.80 Difference: $0.7
If DXS meets the Citi target it will return approximately 12% (excluding dividends, fees and charges).
Current consensus price target is $6.49, suggesting upside of 10.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 37.00 cents and EPS of 63.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 58.5, implying annual growth of 355.6%. Current consensus DPS estimate is 37.0, implying a prospective dividend yield of 6.3%. Current consensus EPS estimate suggests the PER is 10.1. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 37.00 cents and EPS of 63.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 61.4, implying annual growth of 5.0%. Current consensus DPS estimate is 36.5, implying a prospective dividend yield of 6.2%. Current consensus EPS estimate suggests the PER is 9.6. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates DXS as Outperform (1) -
First Impressions: Dexus' FY26 AFFO of 45.0cps, broadly in line with Macquarie and guidance, supported by development completions, higher occupancy and stronger leasing spreads.
FY27 AFFO guidance of 37.5c-39.5cps implies a -14% decline at the midpoint and is below consensus.
This reflects lower trading profits and performance fees, funds management headwinds and higher finance costs, although DPS guidance of 37.0cps is well ahead of the analyst's expectations.
Macquarie highlights improving office occupancy of 95.7% and strong industrial leasing spreads of around 24%, while the industrial portfolio remains 8.1% under-rented, providing scope for further rental growth.
Outperform with a $7.06 target.
Target price is $7.06 Current Price is $5.80 Difference: $1.26
If DXS meets the Macquarie target it will return approximately 22% (excluding dividends, fees and charges).
Current consensus price target is $6.49, suggesting upside of 10.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 37.00 cents and EPS of 44.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 58.5, implying annual growth of 355.6%. Current consensus DPS estimate is 37.0, implying a prospective dividend yield of 6.3%. Current consensus EPS estimate suggests the PER is 10.1. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 36.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 61.4, implying annual growth of 5.0%. Current consensus DPS estimate is 36.5, implying a prospective dividend yield of 6.2%. Current consensus EPS estimate suggests the PER is 9.6. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates DXS as Neutral (3) -
First Read: Dexus' FY26 result was broadly in line, but FY27 AFFO guidance implies a -14% y/y decline and is around -3% below consensus.
Office occupancy improved to 95.7% and industrial like-for-like income growth remained strong at 8.3%, although industrial occupancy eased to 94.6%.
The broker highlights uncertainty around the strategic review of the $7.3bn infrastructure platform, which is expected to make a materially lower earnings contribution in FY27, while redemption requests have increased at the Dexus Healthcare Property Fund.
Neutral. Target $6.12.
Target price is $6.12 Current Price is $5.80 Difference: $0.32
If DXS meets the UBS target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $6.49, suggesting upside of 10.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 37.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 58.5, implying annual growth of 355.6%. Current consensus DPS estimate is 37.0, implying a prospective dividend yield of 6.3%. Current consensus EPS estimate suggests the PER is 10.1. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 35.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 61.4, implying annual growth of 5.0%. Current consensus DPS estimate is 36.5, implying a prospective dividend yield of 6.2%. Current consensus EPS estimate suggests the PER is 9.6. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $19.74
Citi rates EBO as Buy (1) -
Following Ebos Group's FY26 results, Citi maintains its Buy rating but lowers its target by -$2.00 to $22.50.
First Take: EBOS Group's FY26 result was in line with Citi's expectations across the P&L, with revenue of $13.5bn and core EBITDA of $614m, up 10% and 5%, respectively.
Healthcare revenue rose 9% to $12.6bn, while Animal Care revenue increased 35% to $907m, with operational execution tracking plans outlined at the recent strategy day.
FY27 core EBITDA guidance of $635m-$655m brackets consensus, with the midpoint implying around 5% growth, while Citi sits at the top end of the range.
The broker believes guidance could prove conservative as the completed distribution centre network drives benefits over the next 2-3 years.
Target price is $22.50 Current Price is $19.74 Difference: $2.76
If EBO meets the Citi target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $23.81, suggesting upside of 21.6% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 121.8, implying annual growth of N/A. Current consensus DPS estimate is 102.0, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
Current consensus EPS estimate is 137.4, implying annual growth of 12.8%. Current consensus DPS estimate is 109.8, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 14.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates EBO as Outperform (1) -
Ebos Group delivered estimated 4% underlying FY26 earnings growth vs FY25 (ex acquisitions, fuel impacts and fx impacts), in line with Macquarie. FY27 underlying earnings guidance is 4% lower than Macquarie at the mid-point.
The first month of First Pharmaceutical Wholesaler Agreement (1PWA) for Symbion has been a small drag on earnings. The broker thinks this and Community Service Organisation (CSO) funding uplift will become a decent tailwind into the second half.
Catalyst risks are skewed to upside, Macquarie suggests. Defensive characteristics were questioned post FY25 but long term data bears out defensive nature of animal/healthcare segments.
Target falls to NZ$34.90 from NZ$36.44, Outperform retained.
Current Price is $19.74. Target price not assessed.
Current consensus price target is $23.81, suggesting upside of 21.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 94.30 cents and EPS of 132.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 121.8, implying annual growth of N/A. Current consensus DPS estimate is 102.0, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 107.00 cents and EPS of 147.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 137.4, implying annual growth of 12.8%. Current consensus DPS estimate is 109.8, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 14.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates EBO as Buy (1) -
Morgans maintains a Buy rating for Ebos Group with its target price increased to $22.93 from $22.92 following a financial result and guidance update in line with consensus expectations.
The analyst highlights that revenue reached $13.5bn, up 9.9%, and underlying EBITDA rose 5.0% to $614m despite higher fuel costs and foreign exchange headwinds.
The broker's estimates factor in modest revisions to earnings per share following the completion of a major four-year, $360m distribution centre renewal program.
Management guides toward underlying EBITDA of $635m-$655m for FY27 while anticipating a return to earnings per share growth from FY28.
The valuation is supported by a combined discounted cash flow and price-to-earnings comparable companies methodology.
Target price is $22.93 Current Price is $19.74 Difference: $3.19
If EBO meets the Morgans target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $23.81, suggesting upside of 21.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 100.00 cents and EPS of 117.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 121.8, implying annual growth of N/A. Current consensus DPS estimate is 102.0, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 107.00 cents and EPS of 137.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 137.4, implying annual growth of 12.8%. Current consensus DPS estimate is 109.8, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 14.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates EBO as Buy (1) -
Ord Minnett maintains its Buy rating for Ebos Group but lowers its target to $26.00 from $28.00 following an in-line FY26 result.
EBITDA increased 5% to $614m as underlying growth of around 9% was partly offset by fuel and currency headwinds, while FY27 guidance implies EBITDA of $635m-$655m.
Completion of the distribution-centre renewal program should reduce FY27 capital expenditure by -31% and support cash flow, returns and further bolt-on acquisitions.
Forecasts were revised for earnings, working capital and the valuation roll-forward. The report identifies wholesale competition and the loss of Chemist Warehouse New Zealand business as the main risks.
Target price is $26.00 Current Price is $19.74 Difference: $6.26
If EBO meets the Ord Minnett target it will return approximately 32% (excluding dividends, fees and charges).
Current consensus price target is $23.81, suggesting upside of 21.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 94.80 cents and EPS of 118.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 121.8, implying annual growth of N/A. Current consensus DPS estimate is 102.0, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 104.10 cents and EPS of 130.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 137.4, implying annual growth of 12.8%. Current consensus DPS estimate is 109.8, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 14.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates EBO as Buy (1) -
EBOS Group's FY26 result was broadly in line with UBS expectations, with 2H26 underlying EBITDA rising 7% to $314m as slightly weaker Healthcare margins were offset by lower operating and corporate costs.
The broker expects FY27 earnings to remain flat due to residual headwinds from the Chemist Warehouse NZ contract loss, higher transport costs and new facility costs, before EPS growth accelerates to a 9% CAGR between FY28-FY30.
FY27-FY29 EPS forecasts are trimmed by -2% to -3% on higher interest costs, while EBITDA forecasts are broadly unchanged and FY27 EBITDA of $649m sits within guidance of $635-$655m.
The broker retains Buy on valuation grounds with an unchanged NZ$26.00 target.
Current Price is $19.74. Target price not assessed.
Current consensus price target is $23.81, suggesting upside of 21.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 119.00 cents and EPS of 119.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 121.8, implying annual growth of N/A. Current consensus DPS estimate is 102.0, implying a prospective dividend yield of 5.2%. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 121.00 cents and EPS of 135.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 137.4, implying annual growth of 12.8%. Current consensus DPS estimate is 109.8, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 14.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
EGL ENVIRONMENTAL GROUP LIMITED
Industrial Sector Contractors & Engineers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $0.09
Bell Potter rates EGL as Buy (1) -
Environmental Group's FY26 result was broadly in line at the EBITDA level, with underlying EBITDA down -22% to $8.7m versus Bell Potter's $8.6m forecast, although revenue missed the broker's expectations.
The $6.1m reported loss was materially impacted by a -$5.7m Airtight Solutions impairment. Operational issues in Energy and delivery delays and Middle East disruptions at Baltec also weighed on earnings, the analyst explains.
Conditions are anticipated to remain challenging but the broker forecasts FY27 normalised EBITDA to recover 20%, supported by improved margins and growing PFAS treatment plant sales. Recurring revenue has increased to 55.3% of group revenue.
FY27/FY28 EPS forecasts are cut by -43%/-49%, respectively. Buy retained on the growing recurring revenue base and valuation.
Target slips to $0.16 from $0.20.
Target price is $0.16 Current Price is $0.09 Difference: $0.073
If EGL meets the Bell Potter target it will return approximately 84% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.90 cents. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 1.10 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $16.35
Ord Minnett rates EOL as Buy (1) -
Ord Minnett maintains Energy One on Buy and increases its target to $18.76 from $18.51 following an in-line FY26 result and the proposed $100m acquisition of GMSL.
Constant-currency annual recurring revenue grew 13% to $64.6m, while elevated churn and slower customer installations tempered the result, Ord Minnett comments.
The broker expects more than 15% recurring revenue growth and a 30% exit cash EBITDA margin in FY27, with GMSL estimated to be 35% EPS accretive before synergies.
Forecasts were rolled forward assuming 16% annual recurring revenue growth in FY27-FY28.
Target price is $18.76 Current Price is $16.35 Difference: $2.41
If EOL meets the Ord Minnett target it will return approximately 15% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 EPS of 38.60 cents. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 EPS of 51.60 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $13.68
Bell Potter rates EVN as Buy (1) -
Bell Potter observes Evolution Mining delivered record FY26 financial metrics, strong free cash flow (FCF) and significant balance sheet improvement.
The board declared a fully franked final dividend of 21c, below the broker's 25c forecast, bringing FY26 distributions to 41c. The broker highlights an increased dividend payout target of around 60% of group cash flow.
FY26 revenue of $5.56bn and underlying earnings (EBITDA) of $3.17bn reflected strong operations and effectively unhedged gold exposure, the analysts explain. FY27 production and cost guidance broadly matched Bell Potter's expectations.
FY27, FY28 and FY29 EPS forecasts fall -6%, -3% and -3%, respectively, following updated production and cost assumptions.
Bell Potter raises its target to $15.55 from $15.10 and maintains its Buy rating.
Target price is $15.55 Current Price is $13.68 Difference: $1.87
If EVN meets the Bell Potter target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $13.88, suggesting downside of -7.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 45.00 cents and EPS of 106.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 91.0, implying annual growth of N/A. Current consensus DPS estimate is 44.3, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 16.6. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 50.00 cents and EPS of 129.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.0, implying annual growth of 15.4%. Current consensus DPS estimate is 44.9, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 14.4. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates EVN as Neutral (3) -
Evolution Mining's FY26 earnings, revenue and profit were broadly in line with consensus, Macquarie reports. The dividend payout ratio increased from 50% to 60% of group cashflow, underpinning Evolution's focus on returning capital to shareholders.
FY27 gold/copper production guidance is slightly below consensus. FY27 cost guidance is 5% higher and FY27 growth capex guidance is 10% higher, Macquarie notes, with additional capital for growth studies and other pre-development work.
Evolution's strong track record of delivery continues, and the company can't be faulted for accelerating growth capital to advance key assets, but in Macquarie's view the stock is trading at a fair valuation.
Target rises to $12.50 from $11.50, Neutral retained.
Target price is $12.50 Current Price is $13.68 Difference: minus $1.18 (current price is over target).
If EVN meets the Macquarie target it will return approximately minus 9% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $13.88, suggesting downside of -7.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 26.00 cents and EPS of 76.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 91.0, implying annual growth of N/A. Current consensus DPS estimate is 44.3, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 16.6. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 50.00 cents and EPS of 98.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.0, implying annual growth of 15.4%. Current consensus DPS estimate is 44.9, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 14.4. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates EVN as Downgrade to Hold from Buy (3) -
Morgans moves its recommendation for Evolution Mining to Hold from Buy with its target price decreased to $14.40 from $14.60 following an in-line FY26 result and the declaration of a final dividend of 21cps.
The analyst highlights the dividend payout policy increased to 60% of group cash flow from 50%, while FY27 guidance aligns closely with consensus expectations alongside increased capital expenditure for key growth assets.
The broker's estimates factor in minor forecast adjustments to FY27 production and capital expenditure profiles.
Management focuses on expanding copper output across Ernest Henry and Northparkes to maintain a diversified asset base.
The valuation is derived from a blended 50:50 discounted cash flow and enterprise value to EBITDA methodology.
Target price is $14.40 Current Price is $13.68 Difference: $0.72
If EVN meets the Morgans target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $13.88, suggesting downside of -7.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 37.10 cents and EPS of 88.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 91.0, implying annual growth of N/A. Current consensus DPS estimate is 44.3, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 16.6. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 60.60 cents and EPS of 111.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.0, implying annual growth of 15.4%. Current consensus DPS estimate is 44.9, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 14.4. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates EVN as Accumulate (2) -
Ord Minnett maintains its Accumulate rating for Evolution Mining and lifts its target to $13.50 from $12.80 after the miner's FY26 result broadly matched expectations.
The 21c final dividend represented a 60% payout, while the balance sheet improved by $849m over the year.
Higher commodity prices could support further distributions and provide capacity for the Northparkes expansion or acquisitions, although FY27 cost and capital expenditure guidance was respectively around 5% and 8% above consensus, the broker observes.
Earnings forecasts changed only marginally.
Target price is $13.50 Current Price is $13.68 Difference: minus $0.18 (current price is over target).
If EVN meets the Ord Minnett target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $13.88, suggesting downside of -7.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 40.60 cents and EPS of 87.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 91.0, implying annual growth of N/A. Current consensus DPS estimate is 44.3, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 16.6. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 26.90 cents and EPS of 84.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.0, implying annual growth of 15.4%. Current consensus DPS estimate is 44.9, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 14.4. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates EVN as Neutral (3) -
Evolution Mining's FY26 underlying EBITDA of $3.17bn was ahead of UBS at $3.10bn, while the 21cps fully franked final dividend was slightly below the 22cps consensus and the payout target was lifted to 60%.
FY27 gold production and cost guidance was broadly in line. Stronger-than-expected copper guidance was partly offset by higher capex, with the analyst lifting FY27 copper production to 68kt and total capex to $1.4bn.
The broker expects gold production to grow 18% to 825kozpa by FY30/31 and sees scope for $2.6bn in dividends over the next three years despite elevated growth investment.
FY27/FY28 EPS forecasts are raised by 7%/4%. Neutral rating retained with a higher target to $13.60 from $13.00.
Target price is $13.60 Current Price is $13.68 Difference: minus $0.08 (current price is over target).
If EVN meets the UBS target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $13.88, suggesting downside of -7.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 62.00 cents and EPS of 95.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 91.0, implying annual growth of N/A. Current consensus DPS estimate is 44.3, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 16.6. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 37.00 cents and EPS of 101.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 105.0, implying annual growth of 15.4%. Current consensus DPS estimate is 44.9, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 14.4. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
FBU FLETCHER BUILDING LIMITED
Building Products & Services
More Research Tools In Stock Analysis - click HERE
Overnight Price: $3.35
Citi rates FBU as Neutral (3) -
In the wake of Fletcher Building's FY26 results, Citi raises its target to NZ$4.10 from NZ$3.70 and remains Neutral-rated.
First Take: Citi notes Fletcher Building's FY26 EBIT of NZ$414m was around 5% ahead of consensus and above the company's NZ$400-NZ$403m guidance, with all segments exceeding expectations.
The bulk of the year-on-year EBIT growth came from Wood and Panels, while net debt declined to $637m, or 1.1x, and there was no increase in the Iplex provision.
Management provided only qualitative FY27 guidance, with 1H27 expected to be affected by demand pulled forward into 2H26 ahead of price increases and ongoing macro uncertainty.
The analyst explains that, adjusting for -NZ$52m of land sales in FY26, consensus FY27 EBIT of NZ$396m implies around 9% growth, which is considered achievable given the strong 2H26 exit rate across building products.
Current Price is $3.35. Target price not assessed.
Current consensus price target is $2.76, suggesting downside of -18.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Current consensus EPS estimate is 16.0, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 21.3. |
Forecast for FY28:
Current consensus EPS estimate is 20.2, implying annual growth of 26.2%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 16.8. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates FBU as Underperform (5) -
Fletcher Building's FY26 pre-significant items continuous operational earnings were 3% above guidance and Macquarie. Net debt is -13% lower than guidance.
Cautious outlook comments were largely unchanged. Macquarie notes the recent improvement seen in core volume bellwethers in the June Q and three-times upgraded earnings ahead of and into the release may mean the broker's forecast is not the right number.
That said, given a predominant negative risk skew in catalysts, Macquarie retains Underperform. Target rises 9% to NZ$1.89.
Current Price is $3.35. Target price not assessed.
Current consensus price target is $2.76, suggesting downside of -18.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of 15.55 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.0, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 21.3. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 0.00 cents and EPS of 16.66 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 20.2, implying annual growth of 26.2%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 16.8. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates FBU as Underweight (5) -
On a quick look, Morgan Stanley notes earnings of NZ$414m exceeded Fletcher Building's NZ$400m–NZ$403m July guidance, including NZ$52m of property sales.
It was a modest beat, and the recovery is still gradual on a mix of divisional outcomes. Second half volumes improved, but some demand was pulled forward.
The first half FY27 remains uncertain, Morgan Stanley suggests, and no meaningful underlying recovery is expected until 2027.
Underweight and $2.76 target retained. Industry view is in-line.
Target price is $2.76 Current Price is $3.35 Difference: minus $0.59 (current price is over target).
If FBU meets the Morgan Stanley target it will return approximately minus 18% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $2.76, suggesting downside of -18.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.0, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 21.3. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 EPS of 22.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 20.2, implying annual growth of 26.2%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 16.8. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates FBU as Neutral (3) -
Fletcher Building's FY26 EBIT before significant items of NZ$414m was 3% above UBS at NZ$400m, with the broker seeing signs the restructuring is gaining traction through market share gains and margin recovery ahead of a meaningful volume rebound.
Volumes are expected to remain subdued until calendar 2027, but the analyst lifts its FY27 EBIT forecast by 8% to NZ$387m on market share gains and improved cost reductions.
Dividends are anticipated to resume in FY28 rather than FY29. Net debt of NZ$637m was better than expected, although near-term risks include destocking in 1Q27 and weaker activity ahead of the NZ general election in 2Q27.
UBS raises its target to NZ$4.10 from NZ$3.90.
Current Price is $3.35. Target price not assessed.
Current consensus price target is $2.76, suggesting downside of -18.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 16.15 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.0, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 21.3. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 0.00 cents and EPS of 22.95 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 20.2, implying annual growth of 26.2%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 16.8. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $18.06
Macquarie rates FMG as Outperform (1) -
First Impressions: Fortescue's FY26 underlying EBITDA of US$8.6bn was in line with expectations, although underlying earnings of US$3.5bn missed consensus by -6% due to higher exploration expenses and taxes.
Free cash flow of US$3.2bn was 4% ahead of consensus, while the 46cps final dividend was below expectations and represented a 65% payout of underlying earnings.
The analyst highlights the Blacksmith resource and maiden Ore Reserve as supportive of Fortescue's product strategy and its ability to reduce the medium-term strip ratio to 1.5x.
Production, cost and capex guidance is unchanged and broadly in line with consensus. Outperform. Target $20.
Target price is $20.00 Current Price is $18.06 Difference: $1.94
If FMG meets the Macquarie target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $18.97, suggesting upside of 5.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 121.61 cents and EPS of 183.87 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 172.3, implying annual growth of N/A. Current consensus DPS estimate is 98.7, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 10.4. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 83.70 cents and EPS of 128.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 115.6, implying annual growth of -32.9%. Current consensus DPS estimate is 52.0, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 15.5. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $29.22
Citi rates GMG as Buy (1) -
Citi assesses an in-line FY26 result for Goodman Group (at first glance), with its expanding data centre pipeline supporting a compelling multi-year earnings outlook.
A muted market reaction is expected, given the global technology sell-off and elevated bond yields.
Operating EPS rose 10.1% to 129.9c, while FY27 guidance for 9% growth represents an expected starting point, the analysts suggest.
Development work-in-progress surged 53% to $19.7bn, with data centres comprising 78%. Citi forecasts 11% EPS growth in FY27.
The broker expects earnings to accelerate as staged data centre completions unlock income, particularly in FY28, with leasing execution the key catalyst.
Buy rated. Target $40. To reiterate: it's felt the key question for investors is the timing and extent of earnings contributions from recently signed leases and advanced negotiations across FY27 and FY28.
Target price is $40.00 Current Price is $29.22 Difference: $10.78
If GMG meets the Citi target it will return approximately 37% (excluding dividends, fees and charges).
Current consensus price target is $35.01, suggesting upside of 21.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 30.00 cents and EPS of 131.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 129.8, implying annual growth of 52.0%. Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 22.2. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 30.00 cents and EPS of 144.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 142.6, implying annual growth of 9.9%. Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 20.2. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates GMG as Outperform (1) -
First Impressions: Goodman Group's FY26 OEPS rose 10.1% to 129.9cps, slightly ahead of Macquarie and consensus, driven by stronger-than-expected development earnings.
Development momentum remains strong, with work in progress increasing to $19.7bn and data centres now comprising around 78% of total.
Goodman has secured 3.6GW of its 6.4GW global power bank and recently leased 50MW to a hyperscaler in Tokyo.
FY27 guidance for 9% OEPS growth is broadly in line with Macquarie but below consensus, while the balance sheet remains strong with gearing of 6.5%. Macquarie retains Outperform. Target $35.40.
Target price is $35.40 Current Price is $29.22 Difference: $6.18
If GMG meets the Macquarie target it will return approximately 21% (excluding dividends, fees and charges).
Current consensus price target is $35.01, suggesting upside of 21.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 30.00 cents and EPS of 129.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 129.8, implying annual growth of 52.0%. Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 22.2. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 30.00 cents and EPS of 141.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 142.6, implying annual growth of 9.9%. Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 20.2. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates GMG as Buy (1) -
First take: UBS finds Goodman Group's FY26 is in line with expectations. FY27 guidance has remained with 9% EPS growth and that's a bummer because consensus is positioned for 11% growth, including UBS.
Target distribution remains at 30c in FY27.
The broker also notes Australian DC partnership establishment has slipped into 1H27. The analysts look to understand why and will have asked the questions in the subsequent conference call, no doubt.
UBS also finds commentary on logistics activity increasing a positive, although this is not yet matched in the WIP pipeline. Buy. Target $34.09.
Target price is $34.09 Current Price is $29.22 Difference: $4.87
If GMG meets the UBS target it will return approximately 17% (excluding dividends, fees and charges).
Current consensus price target is $35.01, suggesting upside of 21.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 30.00 cents and EPS of 130.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 129.8, implying annual growth of 52.0%. Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 22.2. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 30.00 cents and EPS of 143.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 142.6, implying annual growth of 9.9%. Current consensus DPS estimate is 30.0, implying a prospective dividend yield of 1.0%. Current consensus EPS estimate suggests the PER is 20.2. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.42
Macquarie rates HLS as Neutral (3) -
Healius' FY26 revenue and earnings were largely in line, but interest was ahead of consensus, driving profit down -86% below consensus, Macquarie notes. FY27 earnings guidance is in line, factoring in cost growth up to 3.5% and like-for-like pathology volume growth in line with the industry.
Management expects Health Professional Award wages to increase 5%pa to FY31 in addition to Annual Wage Reviews. Given wage pressures and subdued GP attendances, and growth in telehealth, earnings margin guidance has been watered down.
While margins are improving due to cost-out savings, Macquarie remains cautious given Healius faces ongoing wage pressures from the Fair Work Commission gender undervaluation case and subdued GP attendances.
Target rises to 45c from 39c, Neutral retained.
Target price is $0.45 Current Price is $0.42 Difference: $0.03
If HLS meets the Macquarie target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $0.48, suggesting upside of 2.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 1.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is -0.7, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is N/A. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 0.00 cents and EPS of 0.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 0.7, implying annual growth of N/A. Current consensus DPS estimate is 0.5, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 67.1. |
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates HLS as Hold (3) -
Morgans maintains a Hold rating for Healius with its target price increased to $0.43 from $0.41 following a mixed FY26 result.
The analyst notes underlying revenue increased 2.1% to $1,373m while underlying EBITDA rose 7.6% to $259m, though underlying EBIT fell short of consensus due to thin pathology margins.
Management reported positive momentum in Agilex alongside contained group costs, but noted that fair work commission impacts have extended the timeline for mid-to-high single-digit EBIT margins to December 2028.
The broker's estimates factor in forecast adjustments across FY27 and FY28 following these operating headwinds and delayed margin targets.
The valuation is supported by a blended discounted cash flow, price-to-earnings, and enterprise value to EBITDA methodology.
Target price is $0.43 Current Price is $0.42 Difference: $0.01
If HLS meets the Morgans target it will return approximately 2% (excluding dividends, fees and charges).
Current consensus price target is $0.48, suggesting upside of 2.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is -0.7, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is N/A. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 1.00 cents and EPS of 0.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 0.7, implying annual growth of N/A. Current consensus DPS estimate is 0.5, implying a prospective dividend yield of 1.1%. Current consensus EPS estimate suggests the PER is 67.1. |
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.35
Ord Minnett rates HSN as Buy (1) -
Ord Minnett maintains Hansen Technologies on Buy but reduces its target to $5.67 from $6.72, down -15.6%, after weak FY27 guidance prompted a material earnings reset.
FY26 revenue of $387m missed the broker’s $399m forecast, although underlying EBITDA of $120m was broadly in line, while FY27 guidance implies flat revenue and a margin contraction to 26% from 31%.
The broker cuts its FY27 underlying EBITDA estimate by $35m, or -26%, but believes investment in sales, research and NOVA AI could lift longer-term organic growth and improve platform efficiency.
Outer-year forecasts were also reduced; execution of the investment program and the transition away from licence fees are considered the main risks.
Target price is $5.67 Current Price is $3.35 Difference: $2.32
If HSN meets the Ord Minnett target it will return approximately 69% (excluding dividends, fees and charges).
Current consensus price target is $6.29, suggesting upside of 95.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 10.00 cents and EPS of 26.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 31.6, implying annual growth of N/A. Current consensus DPS estimate is 10.0, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 10.2. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 10.00 cents and EPS of 32.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 32.6, implying annual growth of 3.2%. Current consensus DPS estimate is 10.0, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 9.9. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
HUB HUB24 LIMITED
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $79.74
Morgans rates HUB as Accumulate (2) -
Morgans retains an Accumulate rating for Hub24 with its target price trimmed to $92.00 following a broadly in-line FY26 group result.
The analyst highlights underlying EBITDA of $211.4m, up 30% on pcp, and underlying NPAT of $137.3m, although platform revenue and operating momentum softened in the second half due to elevated discretionary gross outflows.
The broker's estimates factor in minor EPS adjustments of plus or minus 1% across FY27 and FY28 following near-term flow headwinds.
Management maintains a long-term funds under administration target of $186bn to $200bn by FY28-end.
The valuation is supported by a discounted cash flow methodology.
Target price is $92.00 Current Price is $79.74 Difference: $12.26
If HUB meets the Morgans target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $95.51, suggesting upside of 24.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 93.00 cents and EPS of 179.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 187.7, implying annual growth of 27.3%. Current consensus DPS estimate is 91.2, implying a prospective dividend yield of 1.2%. Current consensus EPS estimate suggests the PER is 40.7. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 111.00 cents and EPS of 208.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 219.1, implying annual growth of 16.7%. Current consensus DPS estimate is 106.1, implying a prospective dividend yield of 1.4%. Current consensus EPS estimate suggests the PER is 34.9. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.17
UBS rates IEL as Buy (1) -
First Read: UBS expects IDP Education's FY26 result and FY27 outlook to disappoint the market today, with weak student placement volumes and ongoing regulatory headwinds overshadowing strong cost reductions and cash generation.
FY27 adjusted EBIT guidance is around -9% below consensus at the midpoint, reflecting expectations for market volumes to fall another -20% to -30%.
The analyst highlights $32m of FY26 cost savings and a further $15m net reduction targeted in FY27, while strong cash conversion reduced gearing to 1.0x and supported a $50m share buyback.
UBS believes management is controlling what it can, and anticipates the difficult operating environment to persist through FY27. Earnings forecasts are likely to be downgraded.
Buy. Target $5.15.
Target price is $5.15 Current Price is $2.17 Difference: $2.98
If IEL meets the UBS target it will return approximately 137% (excluding dividends, fees and charges).
Current consensus price target is $3.60, suggesting upside of 109.3% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 5.00 cents and EPS of 22.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.3, implying annual growth of 45.7%. Current consensus DPS estimate is 4.3, implying a prospective dividend yield of 2.5%. Current consensus EPS estimate suggests the PER is 7.4. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 6.00 cents and EPS of 21.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 21.3, implying annual growth of -8.6%. Current consensus DPS estimate is 7.2, implying a prospective dividend yield of 4.2%. Current consensus EPS estimate suggests the PER is 8.1. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $6.93
Macquarie rates ILU as Outperform (1) -
Iluka Resources' first half metrics were largely pre-released, with revenue and net debt in line. The underlying loss of -$24m was better than Macquarie expected.
The inventory drawdown continues, reducing mineral sands division net debt by -$200m in the first half and supporting balance sheet flexibility.
The Balranald ramp-up is still unresolved, Macquarie notes, with both rigs operational and concentrate being produced on specification, but ore extraction rates and recoveries remain below target.
Outperform and $8.00 target retained.
Target price is $8.00 Current Price is $6.93 Difference: $1.07
If ILU meets the Macquarie target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $7.83, suggesting upside of 11.0% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 6.00 cents and EPS of 5.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is -12.1, implying annual growth of N/A. Current consensus DPS estimate is 5.5, implying a prospective dividend yield of 0.8%. Current consensus EPS estimate suggests the PER is N/A. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 7.00 cents and EPS of 94.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 3.6, implying annual growth of N/A. Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 0.9%. Current consensus EPS estimate suggests the PER is 195.8. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates ILU as Overweight (1) -
Iluka Resources' mineral sands revenue, underlying earnings and profit were largely pre-flagged at the June Q update. D&A was -30.0% below Morgan Stanley, reflecting the delay to commercial volumes from Balranald as flagged previously.
The interim dividend was 3.0cps, in line with consensus. 2026 cash cost guidance was cut to -$380m from -$420m, largely reflecting -$35m of Balranald spend shifted from opex to capex following later commissioning.
All other guidance metrics are unchanged. The Balranald ramp-up remains focused on extraction and recoveries, Morgan Stanley notes, while Eneabba remains on schedule for 2027.
Overweight and $8.15 target retained. Industry View: Attractive.
Target price is $8.15 Current Price is $6.93 Difference: $1.22
If ILU meets the Morgan Stanley target it will return approximately 18% (excluding dividends, fees and charges).
Current consensus price target is $7.83, suggesting upside of 11.0% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Morgan Stanley forecasts a full year FY26 EPS of minus 2.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is -12.1, implying annual growth of N/A. Current consensus DPS estimate is 5.5, implying a prospective dividend yield of 0.8%. Current consensus EPS estimate suggests the PER is N/A. |
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of minus 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 3.6, implying annual growth of N/A. Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 0.9%. Current consensus EPS estimate suggests the PER is 195.8. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates ILU as Buy (1) -
Ord Minnett maintains its Buy rating for Iluka Resources with an $8.50 target after an in-line first-half result.
Commentary suggests high inventories should support cash generation without immediately restarting Cataby or the synthetic-rutile kilns, while stabilising the Balranald ramp-up is critical as Jacinth-Ambrosia production declines.
Balranald reaching nameplate capacity and progress towards mid-2027 commissioning of the Eneabba rare-earths refinery are identified as the principal catalysts.
Forecasts were updated by delaying the Cataby and kiln restarts and revising production, sales and inventory assumptions, with little net valuation impact.
Target price is $8.50 Current Price is $6.93 Difference: $1.57
If ILU meets the Ord Minnett target it will return approximately 23% (excluding dividends, fees and charges).
Current consensus price target is $7.83, suggesting upside of 11.0% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Ord Minnett forecasts a full year FY26 dividend of 6.40 cents and EPS of minus 38.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is -12.1, implying annual growth of N/A. Current consensus DPS estimate is 5.5, implying a prospective dividend yield of 0.8%. Current consensus EPS estimate suggests the PER is N/A. |
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 6.30 cents and EPS of minus 46.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 3.6, implying annual growth of N/A. Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 0.9%. Current consensus EPS estimate suggests the PER is 195.8. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates ILU as Neutral (3) -
Iluka Resources' 1H26 EBITDA of $53m missed UBS' forecast at $63m, while the -$24m NPAT (loss) was better than the broker's -$39m forecast and the 3cps interim dividend beat the expected 2cps.
The analyst sees reduced risk around Eneabba, with construction around 60% complete, commissioning on track for calendar 2027, the $1.7-$1.8bn capex budget reaffirmed and funding risk diminishing.
The broker has now removed its previous risk weighting for a stockpile-fed refinery.
Balranald's ramp-up remains slower than expected, while mineral sands markets are showing signs of stabilisation, and UBS makes only minor near-term earnings changes.
The broker retains Neutral but raises its target by 27% to $6.65 from $5.25 on the Eneabba modelling changes.
Target price is $6.65 Current Price is $6.93 Difference: minus $0.28 (current price is over target).
If ILU meets the UBS target it will return approximately minus 4% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $7.83, suggesting upside of 11.0% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 4.00 cents and EPS of minus 14.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is -12.1, implying annual growth of N/A. Current consensus DPS estimate is 5.5, implying a prospective dividend yield of 0.8%. Current consensus EPS estimate suggests the PER is N/A. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 6.00 cents and EPS of minus 21.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 3.6, implying annual growth of N/A. Current consensus DPS estimate is 6.4, implying a prospective dividend yield of 0.9%. Current consensus EPS estimate suggests the PER is 195.8. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MAF MA FINANCIAL GROUP LIMITED
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $6.01
UBS rates MAF as Buy (1) -
First take: UBS finds MA Financial 1H26 normalised EBITDA (ex-LNI) is in-line, with solid momentum to start 2H26 for Lending and CA&E.
Commentary highlights maiden FY29 targets for key operating divisions point to material revenue and margin upside versus consensus.
While near-term earnings were largely in line, the broker highlights the FY29 framework points to medium-term earnings upside versus consensus, assuming management can execute on its growth and margin targets.
Buy. Target $9.30.
Target price is $9.30 Current Price is $6.01 Difference: $3.29
If MAF meets the UBS target it will return approximately 55% (excluding dividends, fees and charges).
Current consensus price target is $8.92, suggesting upside of 25.6% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 26.00 cents and EPS of 47.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 47.3, implying annual growth of 658.0%. Current consensus DPS estimate is 26.1, implying a prospective dividend yield of 3.7%. Current consensus EPS estimate suggests the PER is 15.0. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 32.00 cents and EPS of 58.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 54.8, implying annual growth of 15.9%. Current consensus DPS estimate is 31.7, implying a prospective dividend yield of 4.5%. Current consensus EPS estimate suggests the PER is 13.0. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $1.85
Citi rates MGR as Buy (1) -
Mirvac Group's robust FY26 result and solid FY27 residential outlook reinforce the broker’s Buy rating. The broker's $2.00 target is also unchanged.
In an early assessment, Citi views today's FY26 result by Mirvac Group positively, with in-line EPS of 12.9c, better-than-feared FY27 guidance and a new $200m buyback.
FY27 EPS guidance of 13.2-13.4cpu implies to the broker around 3% growth, while 63% of residential earnings are already secured through pre-sales, the analyst explains.
Gearing declined materially to 24.1%, supporting the buyback, while net tangible assets (NTA) rose 3.1% to $2.33 per security, the analysts highlight.
Mirvac's -25% discount to NTA is noted. Attention is now expected to shift towards execution and development pipeline delivery.
Target price is $2.00 Current Price is $1.85 Difference: $0.15
If MGR meets the Citi target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $2.05, suggesting upside of 7.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 11.50 cents and EPS of 13.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.2, implying annual growth of N/A. Current consensus DPS estimate is 10.2, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 14.4. |
Forecast for FY28:
Citi forecasts a full year FY28 dividend of 12.30 cents and EPS of 15.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.1, implying annual growth of 14.4%. Current consensus DPS estimate is 11.6, implying a prospective dividend yield of 6.1%. Current consensus EPS estimate suggests the PER is 12.6. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates MGR as Outperform (1) -
Mirvac Group' FY26 operating earnings per share of 12.9cps, up 7% year on year, were in line with guidance. FY27 guidance of 13.2-13.4cps compares to prior consensus of 13.2cps and implies 2-4% growth, Macquarie notes.
After three years of asset sales, portfolio repositioning, and working towards improving returns, Mirvac enters FY27 with visible growth drivers, Macquarie suggests.
Residential sales and settlement momentum have proven better than feared to date, underpinning confidence in the group's growth outlook. Target rises to $2.25 from $2.17, Outperform retained.
Target price is $2.25 Current Price is $1.85 Difference: $0.4
If MGR meets the Macquarie target it will return approximately 22% (excluding dividends, fees and charges).
Current consensus price target is $2.05, suggesting upside of 7.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 9.90 cents and EPS of 13.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.2, implying annual growth of N/A. Current consensus DPS estimate is 10.2, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 14.4. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 11.00 cents and EPS of 14.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.1, implying annual growth of 14.4%. Current consensus DPS estimate is 11.6, implying a prospective dividend yield of 6.1%. Current consensus EPS estimate suggests the PER is 12.6. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates MGR as Accumulate (2) -
Ord Minnett maintains its Accumulate rating for Mirvac Group and raises its target to $1.95 from $1.85 after strong FY27 guidance outweighed a slightly soft FY26 result.
Operating EPS increased 7% to 12.9c, residential gross margin reached 24% and Mirvac announced a $200m security buyback.
Commentary highlights FY27 guidance for 13.2–13.4c of operating EPS is supported by 2,800–3,100 residential settlements, with 63% already secured.
FY27–FY29 EPS forecasts were raised by 2.0%, 5.5% and 4.5%, respectively.
Target price is $1.95 Current Price is $1.85 Difference: $0.1
If MGR meets the Ord Minnett target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $2.05, suggesting upside of 7.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 10.00 cents and EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.2, implying annual growth of N/A. Current consensus DPS estimate is 10.2, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 14.4. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 12.00 cents and EPS of 16.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.1, implying annual growth of 14.4%. Current consensus DPS estimate is 11.6, implying a prospective dividend yield of 6.1%. Current consensus EPS estimate suggests the PER is 12.6. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates MGR as Neutral (3) -
On further inspection, UBS lifts the target price to $1.99 from $1.97. Neutral rating retained.
EPS forecasts are tweaked lower by -1.5% for FY27 and -1.4% for FY28.
First Take: UBS notes Mirvac Group's FY26 result was broadly in line, with operating EPS of 12.9c matching expectations, and FY27 guidance for 13.2c–13.4c also as anticipated.
Residential development was a key positive, with FY27 settlement guidance of 2,800–3,100 lots well above the broker's forecast and consensus.
Commentary states it is difficult to reconcile with modest EPS growth and implies weaker expectations elsewhere in development.
A $200m on-market buyback is considered a positive, while 4Q26 residential sales softened –11% q/q and –15% on pcp.
Neutral. Target $1.97.
Target price is $1.99 Current Price is $1.85 Difference: $0.14
If MGR meets the UBS target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $2.05, suggesting upside of 7.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 10.00 cents and EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.2, implying annual growth of N/A. Current consensus DPS estimate is 10.2, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 14.4. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 11.00 cents and EPS of 14.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.1, implying annual growth of 14.4%. Current consensus DPS estimate is 11.6, implying a prospective dividend yield of 6.1%. Current consensus EPS estimate suggests the PER is 12.6. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.08
Morgans rates MME as Speculative Buy (1) -
Morgans maintains a Speculative Buy rating for MoneyMe with its target price unchanged at $0.21 following a pre-released FY26 result.
The analyst highlights gross revenue of $249m on a gross loan book surpassing $2bn, alongside a positive normalised NPAT inflection in the second half.
The broker's estimates factor in loan book scaling to $2.35bn by the end of FY27 and normalised NPAT reaching $4m.
Management points to continued origination momentum in Autopay and personal lending alongside sound asset quality.
The valuation is supported by a discounted cash flow and multiples blend methodology.
Target price is $0.21 Current Price is $0.08 Difference: $0.128
If MME meets the Morgans target it will return approximately 156% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 5.90 cents. |
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.20 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $20.34
Citi rates MP1 as Buy (1) -
First Take: Lower operating costs drove Megaport's FY26 beat, with underlying EBITDA excluding share-based compensation rising 24% and coming in 8% ahead of Citi and consensus, while the 25% EBITDA margin exceeded the broker's 23% forecast.
Citi highlights accelerating Network ARR growth, improving NRR and further Latitude contract wins worth US$92m in ARR, while a new $825m debt facility fully funds committed capex.
FY27 guidance is also stronger than expected, with midpoint EBITDA 9% above consensus, although capex is 44% higher and equipment supply constraints have delayed compute procurement for two contracts.
The analyst expects a positive share price reaction.
Buy. Target $22.10
Target price is $22.10 Current Price is $20.34 Difference: $1.76
If MP1 meets the Citi target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $20.85, suggesting upside of 8.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 0.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is -1.8, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is N/A. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 0.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.2, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 106.1. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates MP1 as Buy (1) -
First Read: UBS highlights a strong FY26 result, with EBITDA 8% ahead of consensus as both Network and Latitude showed accelerating top-line momentum and improving operating metrics.
Network ARR increased 27% in constant currency and NRR improved to 114%, while Latitude's pipeline strengthened and a new $825m debt package supports further deployment.
FY27 guidance implies EBITDA around 8% above consensus at the midpoint, supported by stronger-than-expected Compute revenue, while capex guidance was materially higher as Latitude investment accelerates.
UBS forecasts are likely to rise, with the broker viewing stronger demand, improving margins and growing cross-sell opportunities as key positives, partly offset by higher D&A and the absence of divisional earnings guidance.
Buy. Target $24.20.
Target price is $24.20 Current Price is $20.34 Difference: $3.86
If MP1 meets the UBS target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $20.85, suggesting upside of 8.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 0.00 cents and EPS of 5.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is -1.8, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is N/A. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 25.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.2, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 106.1. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $5.03
Citi rates MPL as Neutral (3) -
In an initial review of Medibank Private's FY26 results, Citi assesses an in-line outcome and a higher-than-expected dividend. However, underwhelming private health insurance (PHI) growth and a lower Medibank Health gross margin are also noted.
Underlying profit of $637m was in line with consensus of $638m, note the analysts, and 10.9cps fully franked dividend is slightly ahead of consensus.
Softer-than-expected PHI revenue is the main cause of the slight miss to consensus on operating profit with net margins in line, the broker explains.
The analyst would not be surprised to see the stock price trade flat or slightly down today.
Neutral. Target $5.10.
Target price is $5.10 Current Price is $5.03 Difference: $0.07
If MPL meets the Citi target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $5.20, suggesting upside of 10.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 18.50 cents and EPS of 23.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.3, implying annual growth of 28.2%. Current consensus DPS estimate is 18.9, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 20.2. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 20.40 cents and EPS of 25.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.6, implying annual growth of 9.9%. Current consensus DPS estimate is 20.5, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 18.4. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates MPL as Neutral (3) -
First Read: UBS notes Medibank Private's FY26 underlying NPAT was in line with its forecast and consensus, with Health Insurance earnings meeting expectations while Medibank Health fell short.
The FY27 outlook is slightly softer, with 2H26 resident policy growth slowing to 0.2% and elevated policy downgrading reflecting increasing competition and affordability pressures.
Management is targeting market share gains and broadly stable Health Insurance gross margins in FY27, alongside around 25% profit growth from Medibank Health.
UBS sees downside risk to the outlook as rising claims inflation and reinvestment for growth place additional pressure on margins.
Neutral. Target $5.15.
Target price is $5.15 Current Price is $5.03 Difference: $0.12
If MPL meets the UBS target it will return approximately 2% (excluding dividends, fees and charges).
Current consensus price target is $5.20, suggesting upside of 10.5% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 18.80 cents and EPS of 23.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.3, implying annual growth of 28.2%. Current consensus DPS estimate is 18.9, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 20.2. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 20.10 cents and EPS of 25.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.6, implying annual growth of 9.9%. Current consensus DPS estimate is 20.5, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 18.4. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $38.92
Morgans rates NAB as Trim (4) -
Morgans retains a Trim rating for National Australia Bank with its target price reduced to $35.19 from $36.10 following the group's 3Q26 trading update.
The analyst highlights quarterly cash profit growth of 2% trailing consensus expectations, dampened by slower net interest income expansion despite lower credit impairment charges of -$299m.
Management forecasts Australian home lending credit growth slowing to 2.5% in FY27 alongside a -15% sequential decline in quarterly mortgage application values.
The broker's estimates trim FY27 and FY28 earnings by -2% and -5% respectively, reflecting reduced net interest margin assumptions and softer system credit growth.
The valuation incorporates a discounted cash flow methodology supported by a proforma CET1 ratio of 11.3%.
Target price is $35.19 Current Price is $38.92 Difference: minus $3.73 (current price is over target).
If NAB meets the Morgans target it will return approximately minus 10% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $38.87, suggesting upside of 1.1% (ex-dividends)
The company's fiscal year ends in September.
Forecast for FY26:
Morgans forecasts a full year FY26 dividend of 170.00 cents and EPS of 207.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 210.8, implying annual growth of -4.6%. Current consensus DPS estimate is 170.0, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 18.2. |
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 170.00 cents and EPS of 251.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 243.2, implying annual growth of 15.4%. Current consensus DPS estimate is 170.0, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 15.8. |
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NST NORTHERN STAR RESOURCES LIMITED
Gold & Silver
More Research Tools In Stock Analysis - click HERE
Overnight Price: $22.54
Citi rates NST as Neutral (3) -
First Take: Northern Star Resources' FY26 result was broadly in line with expectations, but Citi views FY27 guidance as weaker than expected due to lower production and higher costs.
Gold production guidance of 1.50-1.65Moz is -3% below consensus at the midpoint, while AISC guidance of $3,050-3,450/oz is 7% above consensus, driven largely by cost pressures at Yandal and Pogo.
The analyst sees downside risk to FY27 earnings and expects investor attention to shift towards execution of the KCGM ramp-up, where the Mill Expansion project cost has increased to $1.75-1.81bn.
The broker also highlights uncertainty over whether Yandal's elevated cost base will persist beyond FY27 and potential strategic changes under the incoming CEO.
Neutral Target $24.30.
Target price is $24.30 Current Price is $22.54 Difference: $1.76
If NST meets the Citi target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $25.11, suggesting upside of 4.9% (ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 131.0, implying annual growth of 16.3%. Current consensus DPS estimate is 52.8, implying a prospective dividend yield of 2.2%. Current consensus EPS estimate suggests the PER is 18.3. |
Forecast for FY27:
Current consensus EPS estimate is 168.5, implying annual growth of 28.6%. Current consensus DPS estimate is 59.8, implying a prospective dividend yield of 2.5%. Current consensus EPS estimate suggests the PER is 14.2. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates NST as Neutral (3) -
First impressions: Northern Star Resources' FY26 result was broadly in line with expectations, with underlying NPAT beating consensus by 2% and the 55cps total dividend 5% ahead.
Macquarie views FY27 guidance as mixed, with gold sales of 1,575koz at the midpoint -3% below consensus and AISC of $3,250/oz 7% above, driven largely by higher costs at Yandal.
Growth capex guidance of $1.86bn was a positive, coming in -4% below consensus, while KCGM was the only operation to deliver sales guidance above expectations.
Neutral rating with a $23 target. Northern Star is expected to lag gold peers despite the stronger overnight gold price due to softer FY27 sales and cost guidance.
Target price is $23.00 Current Price is $22.54 Difference: $0.46
If NST meets the Macquarie target it will return approximately 2% (excluding dividends, fees and charges).
Current consensus price target is $25.11, suggesting upside of 4.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 53.00 cents and EPS of 114.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 131.0, implying annual growth of 16.3%. Current consensus DPS estimate is 52.8, implying a prospective dividend yield of 2.2%. Current consensus EPS estimate suggests the PER is 18.3. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 44.00 cents and EPS of 127.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 168.5, implying annual growth of 28.6%. Current consensus DPS estimate is 59.8, implying a prospective dividend yield of 2.5%. Current consensus EPS estimate suggests the PER is 14.2. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
NWH NRW HOLDINGS LIMITED
Mining Sector Contracting
More Research Tools In Stock Analysis - click HERE
Overnight Price: $7.21
UBS rates NWH as Buy (1) -
First Read: UBS highlights a strong FY26 result from NRW Holdings, with revenue and earnings ahead of expectations as Mining, Civil and EMIT produced stronger 2H26 margins.
The order book remains solid at $7.5bn, while the pipeline has increased to $29.1bn and cash conversion was around 94%. FY27 revenue and EBITA guidance are both ahead of UBS and consensus at the midpoint, with the broker noting the implied EBITA margin rises to 6.9%.
UBS forecasts are likely to increase and, given NRW's history of progressively upgrading guidance, the broker believes the initial FY27 outlook could prove conservative.
Buy. Target $7.95.
Target price is $7.95 Current Price is $7.21 Difference: $0.74
If NWH meets the UBS target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $7.90, suggesting upside of 4.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 19.00 cents and EPS of 37.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 37.7, implying annual growth of 522.1%. Current consensus DPS estimate is 19.5, implying a prospective dividend yield of 2.6%. Current consensus EPS estimate suggests the PER is 20.1. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 23.00 cents and EPS of 42.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 42.0, implying annual growth of 11.4%. Current consensus DPS estimate is 22.7, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 18.1. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.08
Ord Minnett rates NXD as Speculative Buy (1) -
NextEd Group retains its Speculative Buy rating at Ord Minnett but the broker cuts its target to $0.24 from $0.36, down -33.3%.
Commentary suggests the company has released resilient FY26 earnings in a difficult education market. Underlying EBITDA increased 7% to $15.3m despite revenue falling -6.7%, supported by a 55.4% gross margin and $8.5m of permanent cost savings since FY24.
New chief executive Rob Arthur, vocational-course growth and further market-share gains provide potential catalysts, the broker suggests, while the debt-free balance sheet holds $18.2m of cash.
EBITDA forecasts were reduced by -9% to -11% after revising student assumptions.
Target price is $0.24 Current Price is $0.08 Difference: $0.16
If NXD meets the Ord Minnett target it will return approximately 200% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.20 cents. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 0.00 cents and EPS of 1.00 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
PME PRO MEDICUS LIMITED
Medical Equipment & Devices
More Research Tools In Stock Analysis - click HERE
Overnight Price: $198.85
Morgan Stanley rates PME as Overweight (1) -
Pro Medicus posted a small FY26 beat, Morgan Stanley notes. Revenue rose 23% year on year, and earnings 24%. Adverse FX clipped revenue growth by -5%.
The broker has a higher conviction in a positive thesis after FY26 results. Most critical was a clearer enunciation of the key drivers of 30% revenue growth in FY27 and beyond – including the rollout of recent contracts, new logo wins, new products, and new geographies.
Pro Medicus also delivered more evidence of an effective AI moat. Target rises to $220 from $200, Overweight retained. Industry view: Attractive.
Target price is $220.00 Current Price is $198.85 Difference: $21.15
If PME meets the Morgan Stanley target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $228.33, suggesting upside of 10.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 92.50 cents and EPS of 185.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 196.2, implying annual growth of -22.7%. Current consensus DPS estimate is 93.5, implying a prospective dividend yield of 0.5%. Current consensus EPS estimate suggests the PER is 105.0. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 121.30 cents and EPS of 243.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 252.3, implying annual growth of 28.6%. Current consensus DPS estimate is 117.4, implying a prospective dividend yield of 0.6%. Current consensus EPS estimate suggests the PER is 81.7. |
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.80
UBS rates RDX as Buy (1) -
First Read: Redox's FY26 result was broadly in line at the EBITDA and underlying NPAT level, with stronger-than-expected gross margins a key positive.
Revenue increased 7% y/y and EBITDA rose 10% y/y, while operating cash flow jumped 84%, supported by improved working capital, leaving the company with $77m net cash.
US organic revenue growth of 34% was also ahead of the broker's forecast, driven by new products and increased share of wallet.
Buy. Target $4.20.
Target price is $4.20 Current Price is $3.80 Difference: $0.4
If RDX meets the UBS target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $3.83, suggesting upside of 6.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 13.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.8, implying annual growth of 14.4%. Current consensus DPS estimate is 12.4, implying a prospective dividend yield of 3.5%. Current consensus EPS estimate suggests the PER is 21.4. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 16.00 cents and EPS of 21.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.9, implying annual growth of 18.5%. Current consensus DPS estimate is 14.5, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 18.0. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.00
UBS rates RIC as Buy (1) -
First Read: Ridley Corp's FY26 EBITDA was 3% ahead of expectations, although higher finance costs associated with the Fertiliser acquisition and lease interest resulted in underlying NPAT broadly in line.
Fertiliser Distribution was the standout, with 2H26 EBITDA materially ahead of consensus, offset by softer Stockfeeds and Ingredients.
Operating cash flow was also ahead of expectations and net debt finished below the target range, supported by early Fertiliser sales.
Buy. Target $3.20.
Target price is $3.20 Current Price is $3.00 Difference: $0.2
If RIC meets the UBS target it will return approximately 7% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 11.00 cents and EPS of 16.00 cents. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 13.00 cents and EPS of 21.00 cents. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $1.34
Ord Minnett rates SGI as Buy (1) -
Ord Minnett maintains its Buy rating for Stealth Group and raises its target to $1.65 from $1.60 after FY26 NPAT increased 86% to $5.8m.
EBITDA rose 44% to $14.3m and margin expanded 170 basis points to 8.7%, assisted by the Hardware and Building Traders acquisition, while leverage remained low at 0.5 times.
A full-year HBT contribution, organic growth and synergies are expected to drive a significant FY27 step-up, ahead of FY28 targets exceeding $500m of sales and an 8%-12% EBITDA margin.
Target price is $1.65 Current Price is $1.34 Difference: $0.31
If SGI meets the Ord Minnett target it will return approximately 23% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 3.00 cents and EPS of 7.70 cents. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 4.00 cents and EPS of 8.90 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $22.67
Ord Minnett rates SGM as Lighten (4) -
Ord Minnett maintains Sims on Lighten and cuts its target to $21 from $24, down -12.5% while observing underlying FY26 NPAT more than tripled to $289m, beating consensus by 11%.
Stronger metal margins and the SA Recycling joint venture drove the beat, while Sims Lifecycle Services EBIT rose to $173m from $33m.
However, Sims has guided to first-half FY27 Lifecycle Services EBIT of $75-$90m, materially below the $116m consensus forecast, because excess DDR4 supply is depressing secondary-market prices.
FY27-FY29 EPS forecasts are raised by 8.5%, 5.1% and 4.8%.
Target price is $21.00 Current Price is $22.67 Difference: minus $1.67 (current price is over target).
If SGM meets the Ord Minnett target it will return approximately minus 7% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $29.28, suggesting upside of 26.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 45.00 cents and EPS of 181.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 181.7, implying annual growth of 42.8%. Current consensus DPS estimate is 55.3, implying a prospective dividend yield of 2.4%. Current consensus EPS estimate suggests the PER is 12.8. |
Forecast for FY28:
Current consensus EPS estimate is 165.0, implying annual growth of -9.2%. Current consensus DPS estimate is 54.0, implying a prospective dividend yield of 2.3%. Current consensus EPS estimate suggests the PER is 14.1. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $4.55
Citi rates SGP as Buy (1) -
Following Stockland's FY26 results, Citi raises its target by 30c to $5.40 and maintains a Buy rating.
On further inspection, Citi stresses the data centre opportunity as extending beyond FY27, with seven sites capable of generating profits from land transfers, development fees and post-completion gains.
Funding requirements may be lower than feared as some sites could be sold as powered land.
MPC margins are expected to decline from FY26's 21.2% as higher-margin projects roll off, although more than 3,800 pre-sales provide solid volume visibility and July's sales slowdown stabilised in August.
Capital is being redirected from office into data centres, logistics and land lease, while the cost of debt is expected to rise to 5.9% in FY27 from 5.3%. Buy rated. Target $5.40.
In an early review, Citi remains positive on Stockland following today's strong FY26 result and FY27 guidance 6% above consensus, supported by data centre development profits.
FY26 funds from operations (FFO) of 36.9cpu was 1% above consensus, while residential settlements of 8,902 also exceeded expectations.
FY27 FFO guidance of 38cpu-39cpu implies to the analyst around 4% growth, with data centre profits the key source of the guidance beat.
Net tangible assets (NTA) rose 4% to $4.39 per security, leaving Stockland trading at an -8% net tangible asset (NTA) discount, Citi highlights.
Target price is $5.40 Current Price is $4.55 Difference: $0.85
If SGP meets the Citi target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $5.17, suggesting upside of 10.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 25.20 cents and EPS of 38.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 37.2, implying annual growth of N/A. Current consensus DPS estimate is 25.2, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 12.5. |
Forecast for FY28:
Citi forecasts a full year FY28 dividend of 26.70 cents and EPS of 40.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 38.9, implying annual growth of 4.6%. Current consensus DPS estimate is 26.2, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 12.0. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates SGP as Outperform (1) -
Stockland's FY26 funds from operations rose 9% year on year, at the upper end of the guidance range and in line with consensus. FY27 FFO guidance is well ahead of consensus. Macquarie notes.
Guidance includes initial site-transfer earnings from the proposed data centre developments in partnership with EdgeConneX.
Stockland is executing on strategy, Macquarie notes, has an attractive earnings growth profile and the new partnerships are accretive. Target rises to $5.22 from $4.63, Outperform retained.
Target price is $5.22 Current Price is $4.55 Difference: $0.67
If SGP meets the Macquarie target it will return approximately 15% (excluding dividends, fees and charges).
Current consensus price target is $5.17, suggesting upside of 10.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 25.20 cents and EPS of 35.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 37.2, implying annual growth of N/A. Current consensus DPS estimate is 25.2, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 12.5. |
Forecast for FY28:
Macquarie forecasts a full year FY28 dividend of 26.80 cents and EPS of 39.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 38.9, implying annual growth of 4.6%. Current consensus DPS estimate is 26.2, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 12.0. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates SGP as Equal-weight (3) -
Morgan Stanley points out data centres emerged as the key surprise from Stockland’s FY27 guidance, with FFO per security of 38.0-39.0c including land sell-down profits for the first time.
The broker estimates the underlying business can generate around 37c, implying data centres contribute around $50m-$80m of pre-tax profit, and believes their inclusion in guidance may signal increased confidence around hyperscaler demand.
Stockland has 450MW of secured power plus another four sites in application or planning, with construction potentially commencing within 1-2 years once sites are transferred into the data centre partnership.
Residential activity was softer, with 4QFY26 lot sales falling to 1,936 from 2,164 in 3Q and July sales at 512.
Equal-weight rating and $4.90 target. Industry View: In-Line.
Target price is $4.90 Current Price is $4.55 Difference: $0.35
If SGP meets the Morgan Stanley target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $5.17, suggesting upside of 10.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 25.20 cents and EPS of 36.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 37.2, implying annual growth of N/A. Current consensus DPS estimate is 25.2, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 12.5. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 25.20 cents and EPS of 36.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 38.9, implying annual growth of 4.6%. Current consensus DPS estimate is 26.2, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 12.0. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates SGP as Upgrade to Buy from Neutral (1) -
UBS upgrades Stockland to Buy from Neutral with a higher target of $5.12 from $4.35.
EPS forecasts on further inspection are lifted by 9% for FY27 and 5% for FY28.
First Take: Stockland's FY26 result beat expectations, with residential settlements well ahead of UBS and consensus, while FY27 FFO guidance of 38.0-39.0cps is around 10% above expectations and 6% above consensus at the midpoint.
The analyst suggests the guidance beat likely includes a one-off contribution from land vended into the EdgeConnex partnership, while land lease settlement guidance was also stronger than expected.
The broker views the broader contribution across business lines positively, although FY27 MPC settlement guidance was softer than hoped.
Neutral. Target $4.35.
Target price is $5.12 Current Price is $4.55 Difference: $0.57
If SGP meets the UBS target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $5.17, suggesting upside of 10.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 25.00 cents and EPS of 38.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 37.2, implying annual growth of N/A. Current consensus DPS estimate is 25.2, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 12.5. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 26.00 cents and EPS of 40.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 38.9, implying annual growth of 4.6%. Current consensus DPS estimate is 26.2, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 12.0. |
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SHA SHAPE AUSTRALIA CORPORATION LIMITED
Industrial Sector Contractors & Engineers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $6.65
Morgans rates SHA as Buy (1) -
Morgans maintains a Buy rating for Shape Australia with its target price trimmed to $8.11 from $8.65 following a strong FY26 earnings result.
The analyst highlights revenue of $1,239m, up 30% on pcp, alongside EBITDA of $50.1m and NPAT of $31.7m coming in at the top end of guidance.
The group enters FY27 with a solid order backlog of $628m and an expanding pipeline of $4.8bn, bolstered by recent acquisitions including Arden and APS.
The broker's estimates factor in minor downward revisions of less than -2% to near-term NPAT forecasts alongside the introduction of an equal-weighted PER methodology.
Management's valuation is supported by a blended discounted cash flow and price-to-earnings approach.
Target price is $8.11 Current Price is $6.65 Difference: $1.46
If SHA meets the Morgans target it will return approximately 22% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 36.00 cents and EPS of 43.00 cents. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 38.00 cents and EPS of 46.00 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates SHA as Buy (1) -
Ord Minnett maintains Shape Australia on Buy but lowers its target to $8.55 from $8.85 despite FY26 revenue increasing 29.7% to $1.24bn and exceeding guidance.
Commentary suggests a 9.8% gross margin appears sustainable as Arden and APS contributions expand, while modular construction retains further growth potential.
Award of the proposed $800m-plus DigiCo SYD1 expansion is the major near-term catalyst, alongside hotel, aged-care and acquisition opportunities, the report suggests.
Only minor adjustments have been made to forecasts.
Target price is $8.55 Current Price is $6.65 Difference: $1.9
If SHA meets the Ord Minnett target it will return approximately 29% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 36.00 cents and EPS of 42.30 cents. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 38.50 cents and EPS of 45.30 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.33
Morgan Stanley rates SLC as Overweight (1) -
Morgan Stanley highlights Superloop achieved a robust finish to FY26 with financial metrics largely in line with consensus.
FY26 EBITDA was better than guidance, and cash conversion was strong at 101%, consumer share grew to around 8.8% of new orders versus a 5.2% share.
Capex was noted as the one area of possible concern coming in at the top end of guidance.
Target $3.80. Reiterated Overweight rating. Industry view: In-line.
Target price is $3.80 Current Price is $3.33 Difference: $0.47
If SLC meets the Morgan Stanley target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $3.70, suggesting upside of 18.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of 10.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.7, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 29.3. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 EPS of 12.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.5, implying annual growth of 16.8%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 25.0. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates SLC as Buy (1) -
On further inspection, UBS notes no trading update per se was offered, albeit management indicated it was "encouraged" by momentum in the first six weeks of FY27.
As marketing spend continues to rise to boost brand awareness, and with relatively attractive pricing, the analyst expects the trajectory will remain positive.
The broker remains Buy rated, supported by the robust 34% cash EPS CAGR over 3-years. Target unchanged at $4.15.
First Take: UBS views Superloop's FY26 results as a solid beat, with EBITDA of $123m above guidance and expectations, supported by stronger gross margins and accelerating Consumer subscriber growth.
Operating cash flow was particularly strong at $121m, 15% ahead of the analyst's expectations and consensus, with 101% cash conversion, while capex was only modestly above guidance.
Consumer net adds are viewed as the standout, with recent monthly additions running ahead of forecasts and new order share of 8.8% well above Superloop's 5.2% market share, while FY29 growth ambitions were reiterated.
Buy. Target $4.15.
Target price is $4.15 Current Price is $3.33 Difference: $0.82
If SLC meets the UBS target it will return approximately 25% (excluding dividends, fees and charges).
Current consensus price target is $3.70, suggesting upside of 18.2% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 11.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 10.7, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 29.3. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 0.00 cents and EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.5, implying annual growth of 16.8%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 25.0. |
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SSM SERVICE STREAM LIMITED
Industrial Sector Contractors & Engineers
More Research Tools In Stock Analysis - click HERE
Overnight Price: $2.61
Morgan Stanley rates SSM as Overweight (1) -
Service Stream's FY26 result beat Morgan Stanley across revenue, EBITDA and NPAT, with Transport and Defence performing particularly well and 2H26 margins also exceeding expectations.
The broker sees solid growth visibility from an elevated tender pipeline, with no major renewals or project completions in FY27.
The Defence ramp-up, where management reiterated around $240m of annual revenue and margins are already approaching steady-state levels.
Morgan Stanley lifts FY27-FY28 EPS forecasts by 4%-6%, while seeing medium-term upside from new Defence and Social Infrastructure opportunities, although FY27 earnings are likely to be 2H weighted and SaaS investment is expected to peak at around $22m.
The broker retains Overweight and raises its target to $2.90 from $2.80. Industry View: In-Line.
Target price is $2.90 Current Price is $2.61 Difference: $0.29
If SSM meets the Morgan Stanley target it will return approximately 11% (excluding dividends, fees and charges).
Current consensus price target is $2.88, suggesting upside of 10.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 7.30 cents and EPS of 14.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.3, implying annual growth of N/A. Current consensus DPS estimate is 7.0, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 19.5. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 7.80 cents and EPS of 15.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.0, implying annual growth of 12.8%. Current consensus DPS estimate is 7.8, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 17.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates SSM as Buy (1) -
Ord Minnett maintains Service Stream on Buy and lifts its target to $2.93 from $2.58, up 13.6%, after FY26 EBITDA beat its forecast by 4%.
EBITDA increased 12% to $163.4m, supported by Utilities margin expansion, corporate savings and the new Defence contract, while work in hand reached $8.2bn.
The broker expects continued FY27 growth and sees contract wins, acquisitions and the AGM update as catalysts, supported by $80m of net cash.
FY27 EPS was raised by approximately 1%.
Target price is $2.93 Current Price is $2.61 Difference: $0.32
If SSM meets the Ord Minnett target it will return approximately 12% (excluding dividends, fees and charges).
Current consensus price target is $2.88, suggesting upside of 10.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 7.00 cents and EPS of 14.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.3, implying annual growth of N/A. Current consensus DPS estimate is 7.0, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 19.5. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 7.50 cents and EPS of 15.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.0, implying annual growth of 12.8%. Current consensus DPS estimate is 7.8, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 17.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates SSM as Buy (1) -
On further inspection, UBS raises the target price to $2.95 from $2.85, mostly resulting from EPS forecast upgrades, the analyst states.
With $81m cash on the balance sheet, management is in a good position to pursue more "meaningful" opportunities with a focus on Power and Industrial, highlighted by the broker as most likely.
A decline in work in hand over the next six months is considered as indicative of management's more selective approach. Buy rated.
First Take: Service Stream delivered a better-than-expected FY26 result, with EBITDA 4% ahead of UBS and consensus, driven by strong Asset & Facility Management earnings and improving Utilities margins, partly offset by weaker Telco.
Cash conversion was strong at 114%, while work in hand remained robust at $8.2bn, with 85% of FY27 work secured under contracts or extension options.
The analyst is encouraged by utilities margins reaching 6% in 2H26 and the positive contribution from defence, while management reiterated expectations for 5%–10% annual earnings growth and appears increasingly open to M&A opportunities, the broker comments.
Buy. Target $2.85.
Target price is $2.95 Current Price is $2.61 Difference: $0.34
If SSM meets the UBS target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $2.88, suggesting upside of 10.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 7.00 cents and EPS of 14.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.3, implying annual growth of N/A. Current consensus DPS estimate is 7.0, implying a prospective dividend yield of 2.7%. Current consensus EPS estimate suggests the PER is 19.5. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 8.00 cents and EPS of 15.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.0, implying annual growth of 12.8%. Current consensus DPS estimate is 7.8, implying a prospective dividend yield of 3.0%. Current consensus EPS estimate suggests the PER is 17.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Citi rates STO as Buy (1) -
Santos' 1H26 result and conference call have strengthened Citi's conviction that management is prioritising free cash flow (FCF) growth and shareholder returns.
The broker raises its target to $9.00 from $8.30 and maintains a Buy rating.
First Take: Santos reported 1H26 underlying EBITDA of US$1.57bn, around 1% ahead of Citi and consensus, while underlying earnings of US$397m beat the broker by 13% and consensus by 17%, largely due to a lower tax expense.
The US10.6c interim dividend was ahead of consensus and represented a 100% payout of operating free cash flow, which is viewed as an encouraging signal ahead of the new capital management framework expected with the February result.
Positively, the analyst explains there is ongoing de-risking across Santos' growth portfolio, with Barossa maintaining its targeted eight-day cargo loading cadence, Pikka ramping up and Papua LNG remaining on track for FID in 4Q26.
Calendar 2026 production, sales and cost guidance is unchanged.
Target price is $9.00 Current Price is $8.31 Difference: $0.69
If STO meets the Citi target it will return approximately 8% (excluding dividends, fees and charges).
Current consensus price target is $8.32, suggesting downside of -1.5% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 48.99 cents and EPS of 60.95 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 68.3, implying annual growth of N/A. Current consensus DPS estimate is 46.4, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 12.4. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 56.87 cents and EPS of 63.43 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 67.9, implying annual growth of -0.6%. Current consensus DPS estimate is 60.4, implying a prospective dividend yield of 7.1%. Current consensus EPS estimate suggests the PER is 12.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates STO as Outperform (1) -
Despite a weaker-than-expected June Q and a negative all-in fee cash flow result, Santos is seeing the inflection in its operations and cashflow in real time during the Sep Q, Macquarie suggests.
This is what enabled a strong interim dividend of US11.6cps, which should serve as a signal of things to come as Santos now progresses with free cash flow growth and de-leveraging.
There is growing confidence in a Papua LNG final investment decision timeline by the end of the year, Macquarie notes, with the PNG government-led development forum underway.
Santos remains the broker's sector preference due to its relative value and position in the investment cycle. Target rises to $9.15 from $9.05, Outperform retained.
Target price is $9.15 Current Price is $8.31 Difference: $0.84
If STO meets the Macquarie target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $8.32, suggesting downside of -1.5% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 40.39 cents and EPS of 64.01 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 68.3, implying annual growth of N/A. Current consensus DPS estimate is 46.4, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 12.4. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 58.18 cents and EPS of 57.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 67.9, implying annual growth of -0.6%. Current consensus DPS estimate is 60.4, implying a prospective dividend yield of 7.1%. Current consensus EPS estimate suggests the PER is 12.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates STO as Overweight (1) -
Santos' pre-guided 1H26 result was broadly in line, with EBITDA of US$1.53bn matching Morgan Stanley and consensus, while underlying NPAT beat the broker by 7% and consensus by 18%.
The USD11.6cps interim DPS was also ahead of expectations, representing around 100% of pre-growth free cash flow despite the formal 40% payout policy.
The analyst highlights continued progress at Barossa and Pikka, with Pikka targeting around 80kbbl/d gross production this quarter, while the Moomba optimisation project is expected to deliver more than US$600m in net capex savings.
The next major catalyst is Papua LNG FID targeted for 4Q2026.
Overweight rating and $7.67 target. Industry view In-Line.
Target price is $7.67 Current Price is $8.31 Difference: minus $0.64 (current price is over target).
If STO meets the Morgan Stanley target it will return approximately minus 8% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $8.32, suggesting downside of -1.5% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Morgan Stanley forecasts a full year FY26 EPS of 74.22 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 68.3, implying annual growth of N/A. Current consensus DPS estimate is 46.4, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 12.4. |
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of 80.05 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 67.9, implying annual growth of -0.6%. Current consensus DPS estimate is 60.4, implying a prospective dividend yield of 7.1%. Current consensus EPS estimate suggests the PER is 12.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates STO as Hold (3) -
Ord Minnett maintains Santos on Hold and raises its target to $7.90 from $7.60 following an in-line first-half result and reduced Papua LNG risk.
Revenue increased nearly 2% to US$2.6bn, while underlying NPAT of US$397m beat consensus by 17%, albeit largely because of one-off provisions and hedging items.
Second-half production is expected to rise 20%-30%, supported by Barossa and Pikka, while Papua LNG's final investment decision remains targeted for late 2026.
FY26-FY28 EPS forecasts were raised by 2.3%, 1.9% and 0.7%, respectively.
Target price is $7.90 Current Price is $8.31 Difference: minus $0.41 (current price is over target).
If STO meets the Ord Minnett target it will return approximately minus 5% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $8.32, suggesting downside of -1.5% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Ord Minnett forecasts a full year FY26 dividend of 68.53 cents and EPS of 97.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 68.3, implying annual growth of N/A. Current consensus DPS estimate is 46.4, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 12.4. |
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 90.41 cents and EPS of 100.61 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 67.9, implying annual growth of -0.6%. Current consensus DPS estimate is 60.4, implying a prospective dividend yield of 7.1%. Current consensus EPS estimate suggests the PER is 12.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates STO as Buy (1) -
Post a further look, Santos reiterated it expects the Papua LNG JV to reach FID in 4Q26, with UBS noting potential operator change from TotalEnergies to ExxonMobil could also result in changes to project equity interests.
Stronger equity alignment between Papua LNG and PNG LNG is viewed as a better outcome for shareholders and values Papua LNG at $0.22 per share on a 75% risked basis.
FY26 EPS forecasts rise by more than 5% on stronger commodity prices and PNG production. FY27/FY28 EPS forecasts rise 1%-2% on stronger PNG production, lower royalties and lower exploration costs. No change to Buy rating and $8.30 target.
First Take: A stronger-than-expected interim dividend was the highlight of Santos' 1H26 result, with the USD11.6cps payout 10% ahead of consensus and representing 100% of free cash flow from operations, UBS explains.
Underlying NPAT of US$397m was in line with expectations and 18% ahead of consensus, while EBITDAX was slightly weaker on higher costs.
UBS views the dividend as signalling confidence in a stronger 2H26, with deleveraging and the ramp-up of Barossa and Pikka now key alongside a potential Papua LNG FID in 4Q26.
Buy. Target $8.30.
Target price is $8.30 Current Price is $8.31 Difference: minus $0.01 (current price is over target).
If STO meets the UBS target it will return approximately minus 0% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $8.32, suggesting downside of -1.5% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 52.49 cents and EPS of 72.91 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 68.3, implying annual growth of N/A. Current consensus DPS estimate is 46.4, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 12.4. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 61.24 cents and EPS of 72.91 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 67.9, implying annual growth of -0.6%. Current consensus DPS estimate is 60.4, implying a prospective dividend yield of 7.1%. Current consensus EPS estimate suggests the PER is 12.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $0.16
Bell Potter rates STP as Hold (3) -
Step One Clothing's strategic shift away from deep discounting helped stabilise FY26 gross margins at 75.9%, but revenue fell -26.7%, and adj EBITDA dropped to $1.7m from $17.4m, albeit ahead of Bell Potter's $0.4m forecast.
The broker remains cautious as weaker consumer conditions, reduced promotional activity and elevated marketing investment continue to weigh on sales and operating leverage, cutting FY27–FY29 revenue forecasts by -3%.
FY27 EBITDA forecasts rise by 25% on stronger gross margin assumptions but FY28/FY29 EBITDA forecasts are lowered by -6%, with new product adjacencies not expected to provide a meaningful uplift for some time.
The business reset is expected to take longer than anticipated, and substantial sales growth is required before profitability materially improves.
Hold retained. Target cut to $0.17 from $0.29.
Target price is $0.17 Current Price is $0.16 Difference: $0.015
If STP meets the Bell Potter target it will return approximately 10% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.20 cents. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 0.00 cents and EPS of 0.90 cents. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates STP as Hold (3) -
Morgans maintains a Hold rating for Step One Clothing with a price target of $0.16 following a challenging FY26 financial result shaped by a deliberate pricing and promotional reset.
The analyst notes revenue went down -27% to $63.7m. EBITDA profit of $1.7m excludes a -$9.1m inventory obsolescence provision.
Valuation metrics have been lowered in line with earnings revisions in outer years and softer peer multiples.
The business navigates ongoing headwinds as management works through top-line adjustments and margin stabilisation efforts.
Target price is $0.16 Current Price is $0.16 Difference: $0.005
If STP meets the Morgans target it will return approximately 3% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents. |
Forecast for FY28:
Morgans forecasts a full year FY28 dividend of 1.00 cents and EPS of 1.00 cents. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SUL SUPER RETAIL GROUP LIMITED
Sports & Recreation
More Research Tools In Stock Analysis - click HERE
Overnight Price: $12.56
Citi rates SUL as Buy (1) -
In an early take, Citi remains positive on Super Retail after the release of today's FY26 earnings beat expectations, driven by a materially stronger second-half performance from Rebel.
The broker expects the earnings beat and solid trading update to drive a positive share price reaction, particularly following weakness ahead of the result.
FY26 normalised earnings (EBIT) of $389m beat consensus by around 7%, with Rebel benefiting from stronger sales and a 170bp gross margin improvement, the analyst explains.
Group sales rose 3.5% over the first eight weeks of FY27, while BCF is tracking ahead of Citi's expectations and currency movements should provide further tailwinds.
A 33cps final dividend also exceeded the broker's 24cps forecast.
Buy rating. Target $14.20.
Target price is $14.20 Current Price is $12.56 Difference: $1.64
If SUL meets the Citi target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $13.79, suggesting downside of -4.6% (ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 90.2, implying annual growth of -8.2%. Current consensus DPS estimate is 57.5, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 16.0. |
Forecast for FY27:
Current consensus EPS estimate is 97.6, implying annual growth of 8.2%. Current consensus DPS estimate is 63.2, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 14.8. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates SUL as Outperform (1) -
First Impressions: Super Retail Group's FY26 result was better than expected, with EBITDA up 2% and 4% ahead of Macquarie and consensus, primarily due to lower operating costs and stronger gross margins at Rebel and BCF.
Early FY27 trading is mixed, with Supercheap Auto the standout at 4% LFL growth, while Rebel and BCF remain subdued and Macpac sales have fallen sharply amid warmer winter weather.
The analyst estimates current trading implies around 1.5% upside to its FY27 EPS forecast if sustained, although it questions whether pent-up demand following weak 4Q26 auto consumption has temporarily boosted Supercheap Auto.
Overall, the broker views the result positively given the difficult consumer backdrop, but notes three of the four brands continue to underperform inflation and its expectations.
Outperform. Target $15.80.
Target price is $15.80 Current Price is $12.56 Difference: $3.24
If SUL meets the Macquarie target it will return approximately 26% (excluding dividends, fees and charges).
Current consensus price target is $13.79, suggesting downside of -4.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 54.90 cents and EPS of 92.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 90.2, implying annual growth of -8.2%. Current consensus DPS estimate is 57.5, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 16.0. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 58.70 cents and EPS of 98.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 97.6, implying annual growth of 8.2%. Current consensus DPS estimate is 63.2, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 14.8. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates SUL as Neutral (3) -
First Read: Super Retail Group's FY26 underlying PBT was 7% ahead of consensus and 4% above its forecast, driven particularly by stronger Rebel margins, alongside solid contributions from Supercheap Auto and BCF.
Early FY27 trading was mixed, with group like-for-like sales up 1.5% over the first seven weeks as strength in Supercheap Auto offset weakness in Macpac.
The broker considers overall trading better than feared, while FY27 guidance for group costs and capex is broadly in line with expectations.
Neutral. Target $13.25.
Target price is $13.25 Current Price is $12.56 Difference: $0.69
If SUL meets the UBS target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $13.79, suggesting downside of -4.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 64.00 cents and EPS of 91.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 90.2, implying annual growth of -8.2%. Current consensus DPS estimate is 57.5, implying a prospective dividend yield of 4.0%. Current consensus EPS estimate suggests the PER is 16.0. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 67.00 cents and EPS of 98.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 97.6, implying annual growth of 8.2%. Current consensus DPS estimate is 63.2, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 14.8. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $1.72
Morgans rates SVR as Accumulate (2) -
Morgans retains an Accumulate rating for Solvar with a price target of $1.78 per share following a solid FY26 result that tracked broadly in line with expectations.
The group delivered a normalised net profit after tax of $36.1m, matching guidance of $36.0m, while continuing to execute an orderly exit from New Zealand operations.
The gross loan book expanded 4.8% year-on-year to $953.4m, outperforming the broker's $929m forecast, led by strong Australian receivables growth.
Positive origination momentum observed in the second half of FY26 has carried forward into early FY27, supporting the broader commercial push and book growth objectives.
The analyst notes that net interest income of $145.7m contracted 6% year-on-year due to lower New Zealand income contributions.
Target price is $1.78 Current Price is $1.72 Difference: $0.06
If SVR meets the Morgans target it will return approximately 3% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Morgans forecasts a full year FY26 dividend of 17.00 cents and EPS of 18.00 cents. |
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 17.00 cents and EPS of 19.00 cents. |
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
SXE SOUTHERN CROSS ELECTRICAL ENGINEERING LIMITED
Mining Sector Contracting
More Research Tools In Stock Analysis - click HERE
Overnight Price: $4.48
Bell Potter rates SXE as Buy (1) -
Southern Cross Electrical Engineering's FY26 underlying EBITDA rose 40%, beating Bell Potter's forecast by 2% and guidance by 3%.
Stronger margins and contributions from Force Fire offset lower revenue following completion of several major projects.
The analyst highlights a record $810m order book and multiple large-scale data centre tenders, with FY27 guidance for EBITDA above $100m and a tripling of data centre revenue to $360m reiterated.
The balance sheet is also well positioned for growth, with net cash of $240m following the $150m equity raising, providing capacity to fund working capital and potential acquisitions.
Bell Potter makes no material changes to forecasts, retains Buy and an unchanged $5.40 target.
Target price is $5.40 Current Price is $4.48 Difference: $0.92
If SXE meets the Bell Potter target it will return approximately 21% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 10.50 cents and EPS of 19.60 cents. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 11.00 cents and EPS of 22.10 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $5.36
Morgan Stanley rates TLC as Equal-weight (3) -
Weak jackpot sequencing weighed on The Lottery Corporation's FY26 revenue, but underlying EBITDA of $736m was in line with consensus as disciplined cost management offset softer lottery sales.
Morgan Stanley points out digital penetration was a key positive, rising to 46.6% for FY26 with a significant step-up in 2H26, while operating costs of -$295.9m came in below guidance.
FY27 guidance of $305m-$315m is below consensus at the midpoint.
The broker sees further support from jackpot normalisation and upcoming game changes, including a 16.7% Set for Life price increase expected in September 2026.
Consensus EPS forecasts are expected to remain largely unchanged post result.
Equal-weight. Target $5.60. Industry view: In-Line.
Target price is $5.60 Current Price is $5.36 Difference: $0.24
If TLC meets the Morgan Stanley target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $5.82, suggesting upside of 11.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.2, implying annual growth of N/A. Current consensus DPS estimate is 18.8, implying a prospective dividend yield of 3.6%. Current consensus EPS estimate suggests the PER is 30.2. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.0, implying annual growth of 4.7%. Current consensus DPS estimate is 20.5, implying a prospective dividend yield of 3.9%. Current consensus EPS estimate suggests the PER is 28.9. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates TLC as Buy (1) -
Ord Minnett views The Lottery Corp's FY26 result as resilient despite historically weak jackpot activity, with normalised NPAT of $343m down -6% and -1% below consensus.
Improving digital penetration and lower operating costs are highlighted, which helped limit the earnings impact, while a normalisation in jackpots and the Victorian lotteries licence extension should support FY27.
The broker cuts FY27 to FY29 EPS forecasts by -3.0% to -5.6%, reflecting a slower start to FY27 turnover, updated D&A and interest assumptions, and the online Keno closure. Buy is retained, with the target reduced to $6.40 from $6.60.
Target price is $6.40 Current Price is $5.36 Difference: $1.04
If TLC meets the Ord Minnett target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $5.82, suggesting upside of 11.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 19.00 cents and EPS of 17.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.2, implying annual growth of N/A. Current consensus DPS estimate is 18.8, implying a prospective dividend yield of 3.6%. Current consensus EPS estimate suggests the PER is 30.2. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 20.00 cents and EPS of 18.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.0, implying annual growth of 4.7%. Current consensus DPS estimate is 20.5, implying a prospective dividend yield of 3.9%. Current consensus EPS estimate suggests the PER is 28.9. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates TLC as Buy (1) -
Digital penetration emerged as the key positive from The Lottery Corporation's FY26 result, with underlying EBITDA of $736m in line with UBS and consensus despite unusually weak jackpot outcomes.
The 16.5cps fully franked dividend matched UBS and beat consensus by 4%, while digital penetration increased 1.9% from 1H26.
The analyst expects jackpot normalisation, underlying demand growth and further digital penetration to support high single-digit EPS growth over the longer term, although FY27 jackpot activity has started slowly.
EPS forecasts are largely unchanged, with the broker retaining Buy and trimming its target to $6.10 from $6.15.
Target price is $6.10 Current Price is $5.36 Difference: $0.74
If TLC meets the UBS target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $5.82, suggesting upside of 11.9% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 20.00 cents and EPS of 18.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.2, implying annual growth of N/A. Current consensus DPS estimate is 18.8, implying a prospective dividend yield of 3.6%. Current consensus EPS estimate suggests the PER is 30.2. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 21.00 cents and EPS of 19.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 18.0, implying annual growth of 4.7%. Current consensus DPS estimate is 20.5, implying a prospective dividend yield of 3.9%. Current consensus EPS estimate suggests the PER is 28.9. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences
More Research Tools In Stock Analysis - click HERE
Overnight Price: $16.84
Bell Potter rates TLX as Buy (1) -
Flash Update: Telix Pharmaceuticals delivered a solid 1H26 result, with EBITDA of $52m modestly below Bell Potter's forecast but in line with consensus as higher R&D and marketing expenses weighed.
PSMA revenue was a highlight, rising 27%, while FY26 revenue and R&D spending guidance was maintained and excludes potential revenue from products awaiting regulatory approval.
Operating cash flow was $23m, including $40m received from Replimune, with closing cash of $251m, while underlying NPAT excluding the Replimune payment was broadly in line with the prior year.
Bell Potter notes the key near-term catalyst remains the FDA decision on Pixclara for brain cancer imaging.
Buy. Target $19.
Target price is $19.00 Current Price is $16.84 Difference: $2.16
If TLX meets the Bell Potter target it will return approximately 13% (excluding dividends, fees and charges).
Current consensus price target is $26.23, suggesting upside of 50.9% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY26:
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.23 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 4.9, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 354.7. |
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 29.02 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 21.9, implying annual growth of 346.9%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 79.4. |
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
TPW TEMPLE & WEBSTER GROUP LIMITED
Furniture & Renovation
More Research Tools In Stock Analysis - click HERE
Overnight Price: $4.15
Citi rates TPW as Neutral (3) -
Citi lowers its earnings forecasts for Temple & Webster after FY26 results and cuts its target by -22% to $4.35, while maintaining a Neutral rating.
It's noted the balance sheet remains strong with $123m in cash, although recent share buybacks were undertaken well above the current share price, the broker observes.
In an early take, Citi assesses a strong FY26 result today by Temple & Webster but a weak FY27 trading update, increasing reliance on sustainable margin improvement.
FY26 earnings (EBITDA) of $21.9m exceeded the $20.5m consensus forecast, the analysts observe, while the fourth-quarter earnings margin reached around 6% versus 3.3% for FY26.
Revenue fell -13% on the prior year from July 1 to August 17, although contribution margin dollars rose 10%, the broker explains.
FY27 earnings guidance of $33m–$40m implies to Citi around 50%–80% growth, driven by better unit economics and operating leverage.
Target price is $4.35 Current Price is $4.15 Difference: $0.2
If TPW meets the Citi target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $5.57, suggesting upside of 23.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 0.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.5, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 36.1. |
Forecast for FY28:
Current consensus EPS estimate is 16.0, implying annual growth of 28.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 28.2. |
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates TPW as Downgrade to Equal-weight from Overweight (3) -
Temple & Webster's FY26 sales came in just below the lower end of guidance, while EBITDA of $21.9m reached the upper end, but Morgan Stanley is more concerned by the -13% decline in FY27 year-to-date sales.
The broker believes FY27 earnings now require a larger-than-usual 2H skew and sees increased risk of a strategic recalibration under the new CEO, particularly after the previous circa $40m EBITDA target was widened to $33-40m.
FY27 EBITDA forecasts are reduced to the lower end of guidance. FY27-FY28 EPS forecasts are cut by -32%-41%, with renewed sales growth, operating leverage and market share gains required to rebuild confidence.
The broker downgrades to Equal-weight from Overweight and cuts its target to $4.80 from $8.00. Industry view: In-Line.
Target price is $4.80 Current Price is $4.15 Difference: $0.65
If TPW meets the Morgan Stanley target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $5.57, suggesting upside of 23.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 0.00 cents and EPS of 13.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 12.5, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 36.1. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 0.00 cents and EPS of 16.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.0, implying annual growth of 28.0%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 28.2. |
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $5.60
Citi rates TWE as Buy (1) -
Treasury Wine Estates continues to improve its execution in China, Citi highlights, with Penfolds granting Wajiu Group exclusive distribution rights for several products highlighting this progress.
Wajiu is a large Chinese wine distribution and services group headquartered in Beijing.
Unchanged Buy rating and $6.95 target.
Target price is $6.95 Current Price is $5.60 Difference: $1.35
If TWE meets the Citi target it will return approximately 24% (excluding dividends, fees and charges).
Current consensus price target is $6.34, suggesting upside of 13.4% (ex-dividends)
Forecast for FY27:
Current consensus EPS estimate is 34.8, implying annual growth of N/A. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 16.1. |
Forecast for FY28:
Current consensus EPS estimate is 41.2, implying annual growth of 18.4%. Current consensus DPS estimate is 17.1, implying a prospective dividend yield of 3.1%. Current consensus EPS estimate suggests the PER is 13.6. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UNI UNIVERSAL STORE HOLDINGS LIMITED
Apparel & Footwear
More Research Tools In Stock Analysis - click HERE
Overnight Price: $7.05
Citi rates UNI as Buy (1) -
First Take: Universal Store's FY26 underlying NPAT was slightly ahead of consensus at $39.9m, while the 17cps final dividend beat 14.1cps consensus forecast.
Citi highlights the 140bps improvement in gross margin to 62.5%, while inventory declined despite double-digit revenue growth and 13 net store openings, and the group finished FY26 with $23.3m in net cash.
The key negative was further deterioration in the CTC wholesale business, which incurred another -$23.8m impairment and is considered potentially structurally challenged. Operating costs increased as a percentage of sales.
FY27 trading has started more slowly at Universal Store and THRILLS, although Perfect Stranger remains strong with like-for-like sales growth of 17.6%, the broker points out.
Buy. Target $9.80.
Target price is $9.80 Current Price is $7.05 Difference: $2.75
If UNI meets the Citi target it will return approximately 39% (excluding dividends, fees and charges).
Current consensus price target is $9.71, suggesting upside of 17.0% (ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 52.3, implying annual growth of 72.3%. Current consensus DPS estimate is 39.5, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 15.9. |
Forecast for FY27:
Current consensus EPS estimate is 58.2, implying annual growth of 11.3%. Current consensus DPS estimate is 45.2, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 14.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates UNI as Buy (1) -
First Read: Universal Store's FY26 underlying EBIT was above consensus, in line with UBS' forecast and at the top end of guidance, led by strong Universal Store and Perfect Stranger performance.
Gross margin improved 140bps to 62.5%, while cash conversion remained strong and the group finished FY26 with $23.3m net cash.
Early FY27 trading is encouraging, with like-for-like sales up 2.9% at Universal Store and 17.6% at Perfect Stranger over the first seven weeks, despite tough comparables.
The analyst highlights strong momentum at Perfect Stranger and continued disciplined store expansion.
Buy rated. Target $9.
Target price is $9.00 Current Price is $7.05 Difference: $1.95
If UNI meets the UBS target it will return approximately 28% (excluding dividends, fees and charges).
Current consensus price target is $9.71, suggesting upside of 17.0% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
UBS forecasts a full year FY26 dividend of 37.00 cents and EPS of 52.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 52.3, implying annual growth of 72.3%. Current consensus DPS estimate is 39.5, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 15.9. |
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 45.00 cents and EPS of 58.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 58.2, implying annual growth of 11.3%. Current consensus DPS estimate is 45.2, implying a prospective dividend yield of 5.4%. Current consensus EPS estimate suggests the PER is 14.3. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.53
Citi rates VCX as Neutral (3) -
First take: Vicinity Centres delivered an in-line FY26 result, but Citi sees a meaningful earnings growth inflection in FY27, with FFO guidance of 16.0-16.2cps and AFFO guidance of 13.9c-14.1cps ahead of consensus at the upper end.
Operational performance was strong, with portfolio occupancy reaching a record 99.6%, leasing spreads improving to 4.2% and specialty sales productivity recording a seventh consecutive period of growth.
The analyst highlights fading development drag as a key earnings driver, with lost rent expected to decline to around $18m in FY27 from $27m, while gearing remains conservative at 26.1%.
The broker expects a positive market reaction but retains Neutral. Target $2.70.
Target price is $2.70 Current Price is $2.53 Difference: $0.17
If VCX meets the Citi target it will return approximately 7% (excluding dividends, fees and charges).
Current consensus price target is $2.56, suggesting downside of -2.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 13.20 cents and EPS of 15.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.2, implying annual growth of -31.1%. Current consensus DPS estimate is 12.8, implying a prospective dividend yield of 4.9%. Current consensus EPS estimate suggests the PER is 17.2. |
Forecast for FY27:
Citi forecasts a full year FY27 EPS of 16.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.6, implying annual growth of 2.6%. Current consensus DPS estimate is 13.2, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 16.7. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates VCX as Neutral (3) -
First Impressions: Vicinity Centres' FY26 result was in line with expectations, with FFOps of 15.2cps and AFFOps of 13.0cps matching Macquarie and consensus.
FY27 guidance implies around 6% FFO growth and is broadly in line to slightly ahead of expectations, supported by 3.5% comparable NPI growth and a reduced development-related earnings drag.
The analyst highlights the completion of Chatswood Chase, which is expected to generate more than $250m in development profit, while further projects at Galleria and Uptown provide additional growth.
The broker also points to the strong balance sheet, positive property revaluations and 99.6% occupancy. Neutral with a $2.30 target.
Target price is $2.30 Current Price is $2.53 Difference: minus $0.23 (current price is over target).
If VCX meets the Macquarie target it will return approximately minus 9% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $2.56, suggesting downside of -2.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Macquarie forecasts a full year FY26 dividend of 12.60 cents and EPS of 15.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.2, implying annual growth of -31.1%. Current consensus DPS estimate is 12.8, implying a prospective dividend yield of 4.9%. Current consensus EPS estimate suggests the PER is 17.2. |
Forecast for FY27:
Macquarie forecasts a full year FY27 dividend of 13.40 cents and EPS of 14.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 15.6, implying annual growth of 2.6%. Current consensus DPS estimate is 13.2, implying a prospective dividend yield of 5.1%. Current consensus EPS estimate suggests the PER is 16.7. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
VVA VIVA LEISURE LIMITED
Travel, Leisure & Tourism
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.53
Morgans rates VVA as Buy (1) -
Morgans maintains a Buy rating for Viva Leisure with its target price increased to $2.27 from $2.00 following a strong FY26 financial result that delivered a maiden dividend.
The company achieved record revenue of $237.1m, exceeding guidance across all key metrics after deliberately slowing greenfield expansion to focus on network optimisation.
Average members per club rose to a record 1,351 alongside portfolio utilisation exceeding 80%, while EBITDA margins expanded 50 basis points to 47.4%.
The board declared a maiden dividend of 3.0c per share following the operational turnaround and cash generation.
The broker's estimates lift net profit forecasts by 2% and 8% respectively for FY27 and FY28.
Target price is $2.27 Current Price is $1.53 Difference: $0.745
If VVA meets the Morgans target it will return approximately 49% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 12.00 cents. |
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 3.00 cents and EPS of 13.00 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
WGN WAGNERS HOLDING CO. LIMITED
Building Products & Services
More Research Tools In Stock Analysis - click HERE
Overnight Price: $4.20
Morgans rates WGN as Buy (1) -
Morgans reiterates its Buy rating for Wagners Holding Co with a target price of $5.25 following an FY26 result that beat both prior guidance and expectations.
Strong demand in South East Queensland remains unabated, with key Construction Materials and Composite Fibre Technologies divisions delivering robust earnings growth.
Input costs are expected to pose a drag in FY27, though top-line growth should offset this pressure and support projected earnings per share growth of roughly 10% in FY27 and 16% in FY28.
The stock trades in line with domestic and offshore peers while offering superior growth over the next three years alongside potential Olympic-related catalysts.
Target price is $5.25 Current Price is $4.20 Difference: $1.05
If WGN meets the Morgans target it will return approximately 25% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY26:
Morgans forecasts a full year FY26 dividend of 3.60 cents and EPS of 18.00 cents. |
Forecast for FY27:
Morgans forecasts a full year FY27 dividend of 8.00 cents and EPS of 22.10 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $7.55
Bell Potter rates WHC as Hold (3) -
Bell Potter remains cautious on the outlook for Whitehaven Coal after FY26 underlying earnings missed forecasts and FY27 production and cost guidance underwhelmed.
FY26 underlying earnings (EBITDA) of $1.25bn and profit of $227m missed forecasts, reflecting higher operating and interest costs, the analysts explain.
FY27 guidance is for managed run-of-mine (ROM) production of 38.0-41.0Mt and equity coal sales of 23.9-26.0Mt, compared with 40.3Mt and 26.0Mt in FY26, respectively.
Narrabri faces a nine-week longwall changeout and inflation and currency pressures remain cost headwinds, the analysts highlight.
FY27 and FY28 EPS forecasts fall to 19c and 33c from 39c and 51c, respectively, while FY29 falls -5%. Bell Potter lowers its target to $7.50 from $8.05 and maintains its Hold rating.
Target price is $7.50 Current Price is $7.55 Difference: minus $0.05 (current price is over target).
If WHC meets the Bell Potter target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $8.30, suggesting upside of 8.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Bell Potter forecasts a full year FY27 dividend of 6.00 cents and EPS of 19.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 44.9, implying annual growth of N/A. Current consensus DPS estimate is 15.6, implying a prospective dividend yield of 2.0%. Current consensus EPS estimate suggests the PER is 17.0. |
Forecast for FY28:
Bell Potter forecasts a full year FY28 dividend of 11.00 cents and EPS of 32.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 48.9, implying annual growth of 8.9%. Current consensus DPS estimate is 13.1, implying a prospective dividend yield of 1.7%. Current consensus EPS estimate suggests the PER is 15.6. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates WHC as Overweight (1) -
Whitehaven Coal's FY26 underlying EBITDA was slightly ahead of Morgan Stanley and consensus, supported by cost discipline, while underlying NPAT beat the broker by 1.8% but missed consensus by -7.7% as higher D&A and finance costs weighed.
Cash generation was a highlight, with operating cash flow of $857m and free cash flow of $508m beating consensus by 10.6% and 27%, respectively.
Dividends and allocated buybacks take FY26 shareholder returns to around 70% of underlying NPAT, the analyst points out.
FY27 production and sales guidance is below expectations, reflecting mine sequencing, the planned Narrabri longwall move and Daunia's transition south.
Morgan Stanley considers the outlook conservative, while capex guidance is below forecasts and unit costs are slightly higher.
FY27/FY28 EPS forecasts are lowered by -36.6% and -10.5% accounting for FY27 guidance as well as higher depreciation and non-cash finance costs.
Overweight rated. Target is $8.45. Industry view: Attractive.
Target price is $8.45 Current Price is $7.55 Difference: $0.9
If WHC meets the Morgan Stanley target it will return approximately 12% (excluding dividends, fees and charges).
Current consensus price target is $8.30, suggesting upside of 8.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Morgan Stanley forecasts a full year FY27 dividend of 11.00 cents and EPS of 53.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 44.9, implying annual growth of N/A. Current consensus DPS estimate is 15.6, implying a prospective dividend yield of 2.0%. Current consensus EPS estimate suggests the PER is 17.0. |
Forecast for FY28:
Morgan Stanley forecasts a full year FY28 dividend of 17.00 cents and EPS of 68.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 48.9, implying annual growth of 8.9%. Current consensus DPS estimate is 13.1, implying a prospective dividend yield of 1.7%. Current consensus EPS estimate suggests the PER is 15.6. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates WHC as Buy (1) -
Whitehaven Coal's FY26 result was softer than Ord Minnett expected, although shareholder returns were supported by a 6cps final dividend and matching $47m buyback.
FY27 guidance also disappointed, with equity sales of 23.9Mt to 26.0Mt around -5% below the broker and consensus forecasts, while cost and capex guidance were also higher than expected amid operational issues at Daunia and Narrabri.
Despite this, the analyst forecasts FCF will rise 80% to $890m in FY27, supporting deleveraging and increased shareholder returns as deferred acquisition payments largely fall away.
Forecasts were lowered for production and costs, prompting the target to fall to $9.60 from $10.20, while Buy is retained on valuation and an expected 14% FY27 FCF yield.
Target price is $9.60 Current Price is $7.55 Difference: $2.05
If WHC meets the Ord Minnett target it will return approximately 27% (excluding dividends, fees and charges).
Current consensus price target is $8.30, suggesting upside of 8.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
Ord Minnett forecasts a full year FY27 dividend of 16.30 cents and EPS of 51.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 44.9, implying annual growth of N/A. Current consensus DPS estimate is 15.6, implying a prospective dividend yield of 2.0%. Current consensus EPS estimate suggests the PER is 17.0. |
Forecast for FY28:
Ord Minnett forecasts a full year FY28 dividend of 9.20 cents and EPS of 36.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 48.9, implying annual growth of 8.9%. Current consensus DPS estimate is 13.1, implying a prospective dividend yield of 1.7%. Current consensus EPS estimate suggests the PER is 15.6. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates WHC as Neutral (3) -
After a further look, UBS lowers the target to $7 from $8 and lowers FY27/FY28 EPS forecasts by -18% and -6%, respectively, noting guidance seems to be conservative and is not expected to result in consensus upgrades.
The analyst forecast downgrades reflect lower expected volumes and higher costs, broadly in line with guidance.
Neutral retained.
First Take: Whitehaven Coal's FY26 result was broadly in line, with EBITDA slightly below UBS and consensus, while underlying NPAT of $227m was weaker than expected.
Operational delivery was strong, with production and sales at or above guidance and unit costs down -5% to $132/t.
Net debt of $1.33bn was better than forecast and the 10cps dividend was supplemented by a further $47m buyback.
FY27 guidance is viewed as conservative, with saleable coal volumes declining around -3% at the midpoint and unit costs rising around 6%, while higher capex also weighs on the near-term outlook.
Neutral. Target $8.
Target price is $7.00 Current Price is $7.55 Difference: minus $0.55 (current price is over target).
If WHC meets the UBS target it will return approximately minus 7% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $8.30, suggesting upside of 8.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY27:
UBS forecasts a full year FY27 dividend of 18.00 cents and EPS of 70.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 44.9, implying annual growth of N/A. Current consensus DPS estimate is 15.6, implying a prospective dividend yield of 2.0%. Current consensus EPS estimate suggests the PER is 17.0. |
Forecast for FY28:
UBS forecasts a full year FY28 dividend of 15.00 cents and EPS of 58.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 48.9, implying annual growth of 8.9%. Current consensus DPS estimate is 13.1, implying a prospective dividend yield of 1.7%. Current consensus EPS estimate suggests the PER is 15.6. |
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.58
Citi rates ZIP as Buy (1) -
First Take: Zip Co achieved another earnings beat, with FY26 cash EBITDA rising 58% y/y, 1% ahead of Citi and 2% ahead of consensus, as better cost control offset slightly weaker cash gross profit.
FY27 guidance is viewed positively, with cash EBITDA of $340m sitting 4% above consensus and US TTV expected to grow more than 30% while net bad debts remain within a 1.50%-2.00% range.
The main concern was slowing US TTV growth to 39% in 4Q, below expectations, while US customer numbers were flat quarter on quarter and A&NZ TTV growth slowed to 1%.
Citi sees scope for the shares to outperform on the stronger FY27 earnings outlook, with a further $50m buyback providing additional support.
Buy. Target $3.55.
Target price is $3.55 Current Price is $2.58 Difference: $0.97
If ZIP meets the Citi target it will return approximately 38% (excluding dividends, fees and charges).
Current consensus price target is $3.76, suggesting upside of 23.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY26:
Citi forecasts a full year FY26 dividend of 0.00 cents and EPS of 8.90 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 9.0, implying annual growth of 45.2%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 33.9. |
Forecast for FY27:
Citi forecasts a full year FY27 dividend of 0.00 cents and EPS of 15.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 13.0, implying annual growth of 44.4%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 23.5. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Today's Price Target Changes
| Company | Last Price | Broker | New Target | Prev Target | Change | |
| AEL | Amplitude Energy | $1.71 | Morgans | 2.90 | 3.05 | -4.92% |
| AVH | Avita Medical | $2.82 | Morgans | 2.20 | 1.35 | 62.96% |
| AYA | Artrya | Bell Potter | 6.75 | 6.10 | 10.66% | |
| BRG | Breville Group | $32.18 | Citi | 40.80 | 39.65 | 2.90% |
| Morgan Stanley | 38.00 | 38.20 | -0.52% | |||
| Morgans | 35.55 | 36.75 | -3.27% | |||
| Ord Minnett | 38.00 | 37.20 | 2.15% | |||
| UBS | 37.00 | 36.00 | 2.78% | |||
| BWP | BWP Trust | $3.72 | Macquarie | 3.70 | 3.90 | -5.13% |
| CGF | Challenger | $9.85 | Ord Minnett | 11.70 | 11.00 | 6.36% |
| COH | Cochlear | $136.82 | Morgans | 138.42 | 107.17 | 29.16% |
| COS | Cosol | $0.20 | Ord Minnett | 0.20 | 0.31 | -35.48% |
| DGT | DigiCo Infrastructure REIT | $2.79 | UBS | 3.75 | 4.20 | -10.71% |
| DRR | Deterra Royalties | $4.44 | Ord Minnett | 4.90 | 4.80 | 2.08% |
| EBO | Ebos Group | $19.58 | Citi | 22.50 | 24.50 | -8.16% |
| Morgans | 22.93 | 22.92 | 0.04% | |||
| Ord Minnett | 26.00 | 28.00 | -7.14% | |||
| EGL | Environmental Group | $0.09 | Bell Potter | 0.16 | 0.21 | -23.81% |
| EOL | Energy One | $16.54 | Ord Minnett | 18.76 | 18.51 | 1.35% |
| EVN | Evolution Mining | $15.07 | Bell Potter | 15.55 | 15.10 | 2.98% |
| Macquarie | 12.50 | 11.50 | 8.70% | |||
| Morgans | 14.40 | 14.60 | -1.37% | |||
| Ord Minnett | 13.50 | 12.80 | 5.47% | |||
| UBS | 13.60 | 13.00 | 4.62% | |||
| HLS | Healius | $0.47 | Macquarie | 0.45 | 0.39 | 15.38% |
| Morgans | 0.43 | 0.41 | 4.88% | |||
| HSN | Hansen Technologies | $3.22 | Ord Minnett | 5.67 | 6.77 | -16.25% |
| HUB | Hub24 | $76.48 | Morgans | 92.00 | 112.40 | -18.15% |
| ILU | Iluka Resources | $7.05 | UBS | 6.65 | 5.25 | 26.67% |
| MGR | Mirvac Group | $1.90 | Macquarie | 2.25 | 2.17 | 3.69% |
| Ord Minnett | 1.95 | 1.85 | 5.41% | |||
| UBS | 1.99 | 1.97 | 1.02% | |||
| NAB | National Australia Bank | $38.43 | Morgans | 35.19 | 36.10 | -2.52% |
| NXD | NextEd Group | $0.08 | Ord Minnett | 0.24 | 0.36 | -33.33% |
| PME | Pro Medicus | $206.01 | Morgan Stanley | 220.00 | 200.00 | 10.00% |
| SGI | Stealth Group | $1.42 | Ord Minnett | 1.65 | 1.60 | 3.12% |
| SGM | Sims | $23.24 | Ord Minnett | 21.00 | 24.00 | -12.50% |
| SGP | Stockland | $4.66 | Citi | 5.40 | 5.10 | 5.88% |
| Macquarie | 5.22 | 4.63 | 12.74% | |||
| UBS | 5.12 | 4.35 | 17.70% | |||
| SHA | Shape Australia | $7.00 | Morgans | 8.11 | 8.65 | -6.24% |
| Ord Minnett | 8.55 | 8.85 | -3.39% | |||
| SSM | Service Stream | $2.60 | Morgan Stanley | 2.90 | 2.80 | 3.57% |
| Ord Minnett | 2.93 | 2.58 | 13.57% | |||
| UBS | 2.95 | 2.85 | 3.51% | |||
| STO | Santos | $8.45 | Citi | 9.00 | 8.30 | 8.43% |
| Macquarie | 9.15 | 9.05 | 1.10% | |||
| Ord Minnett | 7.90 | 7.60 | 3.95% | |||
| STP | Step One Clothing | $0.16 | Bell Potter | 0.17 | 0.29 | -41.38% |
| Morgans | 0.16 | 0.20 | -20.00% | |||
| SUL | Super Retail | $14.45 | Macquarie | 15.80 | 15.90 | -0.63% |
| SVR | Solvar | $1.74 | Morgans | 1.78 | 1.65 | 7.88% |
| TLC | Lottery Corp | $5.20 | Ord Minnett | 6.40 | 6.60 | -3.03% |
| UBS | 6.10 | 6.15 | -0.81% | |||
| TPW | Temple & Webster | $4.51 | Citi | 4.35 | 5.60 | -22.32% |
| Morgan Stanley | 4.80 | 8.00 | -40.00% | |||
| VVA | Viva Leisure | $1.57 | Morgans | 2.27 | 2.00 | 13.50% |
| WGN | Wagners Holding Co | $4.67 | Morgans | 5.25 | 5.00 | 5.00% |
| WHC | Whitehaven Coal | $7.63 | Bell Potter | 7.50 | 8.05 | -6.83% |
| Ord Minnett | 9.60 | 10.20 | -5.88% | |||
| UBS | 7.00 | 8.00 | -12.50% |
Summaries
| AEL | Amplitude Energy | Buy - Morgans | Overnight Price $1.64 |
| ALC | Alcidion Group | Buy - Bell Potter | Overnight Price $0.09 |
| APA | APA Group | Buy - Citi | Overnight Price $10.10 |
| Outperform - Macquarie | Overnight Price $10.10 | ||
| Sell - UBS | Overnight Price $10.10 | ||
| AVH | Avita Medical | Downgrade to Sell from Hold - Morgans | Overnight Price $2.71 |
| AYA | Artrya | Buy - Bell Potter | Overnight Price $4.65 |
| BGA | Bega Cheese | Neutral - UBS | Overnight Price $6.01 |
| BHP | BHP Group | Neutral - UBS | Overnight Price $63.71 |
| BRG | Breville Group | Buy - Citi | Overnight Price $31.72 |
| Outperform - Macquarie | Overnight Price $31.72 | ||
| Overweight - Morgan Stanley | Overnight Price $31.72 | ||
| Downgrade to Accumulate from Buy - Morgans | Overnight Price $31.72 | ||
| Buy - Ord Minnett | Overnight Price $31.72 | ||
| Buy - UBS | Overnight Price $31.72 | ||
| BWP | BWP Trust | Neutral - Macquarie | Overnight Price $3.80 |
| Equal-weight - Morgan Stanley | Overnight Price $3.80 | ||
| BXB | Brambles | Buy - Citi | Overnight Price $19.47 |
| Neutral - Macquarie | Overnight Price $19.47 | ||
| CDA | Codan | Neutral - UBS | Overnight Price $43.48 |
| CGF | Challenger | Buy - Ord Minnett | Overnight Price $9.80 |
| COH | Cochlear | Hold - Morgans | Overnight Price $137.30 |
| Neutral - UBS | Overnight Price $137.30 | ||
| COS | Cosol | Downgrade to Hold from Buy - Ord Minnett | Overnight Price $0.20 |
| CSL | CSL | Overweight - Morgan Stanley | Overnight Price $166.48 |
| Buy - UBS | Overnight Price $166.48 | ||
| CWY | Cleanaway Waste Management | Buy - UBS | Overnight Price $2.59 |
| DGT | DigiCo Infrastructure REIT | Buy - UBS | Overnight Price $2.77 |
| DOW | Downer EDI | Outperform - Macquarie | Overnight Price $7.45 |
| Neutral - UBS | Overnight Price $7.45 | ||
| DRR | Deterra Royalties | Accumulate - Ord Minnett | Overnight Price $4.44 |
| DXS | Dexus | Neutral - Citi | Overnight Price $5.80 |
| Outperform - Macquarie | Overnight Price $5.80 | ||
| Neutral - UBS | Overnight Price $5.80 | ||
| EBO | Ebos Group | Buy - Citi | Overnight Price $19.74 |
| Outperform - Macquarie | Overnight Price $19.74 | ||
| Buy - Morgans | Overnight Price $19.74 | ||
| Buy - Ord Minnett | Overnight Price $19.74 | ||
| Buy - UBS | Overnight Price $19.74 | ||
| EGL | Environmental Group | Buy - Bell Potter | Overnight Price $0.09 |
| EOL | Energy One | Buy - Ord Minnett | Overnight Price $16.35 |
| EVN | Evolution Mining | Buy - Bell Potter | Overnight Price $13.68 |
| Neutral - Macquarie | Overnight Price $13.68 | ||
| Downgrade to Hold from Buy - Morgans | Overnight Price $13.68 | ||
| Accumulate - Ord Minnett | Overnight Price $13.68 | ||
| Neutral - UBS | Overnight Price $13.68 | ||
| FBU | Fletcher Building | Neutral - Citi | Overnight Price $3.35 |
| Underperform - Macquarie | Overnight Price $3.35 | ||
| Underweight - Morgan Stanley | Overnight Price $3.35 | ||
| Neutral - UBS | Overnight Price $3.35 | ||
| FMG | Fortescue | Outperform - Macquarie | Overnight Price $18.06 |
| GMG | Goodman Group | Buy - Citi | Overnight Price $29.22 |
| Outperform - Macquarie | Overnight Price $29.22 | ||
| Buy - UBS | Overnight Price $29.22 | ||
| HLS | Healius | Neutral - Macquarie | Overnight Price $0.42 |
| Hold - Morgans | Overnight Price $0.42 | ||
| HSN | Hansen Technologies | Buy - Ord Minnett | Overnight Price $3.35 |
| HUB | Hub24 | Accumulate - Morgans | Overnight Price $79.74 |
| IEL | IDP Education | Buy - UBS | Overnight Price $2.17 |
| ILU | Iluka Resources | Outperform - Macquarie | Overnight Price $6.93 |
| Overweight - Morgan Stanley | Overnight Price $6.93 | ||
| Buy - Ord Minnett | Overnight Price $6.93 | ||
| Neutral - UBS | Overnight Price $6.93 | ||
| MAF | MA Financial | Buy - UBS | Overnight Price $6.01 |
| MGR | Mirvac Group | Buy - Citi | Overnight Price $1.85 |
| Outperform - Macquarie | Overnight Price $1.85 | ||
| Accumulate - Ord Minnett | Overnight Price $1.85 | ||
| Neutral - UBS | Overnight Price $1.85 | ||
| MME | MoneyMe | Speculative Buy - Morgans | Overnight Price $0.08 |
| MP1 | Megaport | Buy - Citi | Overnight Price $20.34 |
| Buy - UBS | Overnight Price $20.34 | ||
| MPL | Medibank Private | Neutral - Citi | Overnight Price $5.03 |
| Neutral - UBS | Overnight Price $5.03 | ||
| NAB | National Australia Bank | Trim - Morgans | Overnight Price $38.92 |
| NST | Northern Star Resources | Neutral - Citi | Overnight Price $22.54 |
| Neutral - Macquarie | Overnight Price $22.54 | ||
| NWH | NRW Holdings | Buy - UBS | Overnight Price $7.21 |
| NXD | NextEd Group | Speculative Buy - Ord Minnett | Overnight Price $0.08 |
| PME | Pro Medicus | Overweight - Morgan Stanley | Overnight Price $198.85 |
| RDX | Redox | Buy - UBS | Overnight Price $3.80 |
| RIC | Ridley Corp | Buy - UBS | Overnight Price $3.00 |
| SGI | Stealth Group | Buy - Ord Minnett | Overnight Price $1.34 |
| SGM | Sims | Lighten - Ord Minnett | Overnight Price $22.67 |
| SGP | Stockland | Buy - Citi | Overnight Price $4.55 |
| Outperform - Macquarie | Overnight Price $4.55 | ||
| Equal-weight - Morgan Stanley | Overnight Price $4.55 | ||
| Upgrade to Buy from Neutral - UBS | Overnight Price $4.55 | ||
| SHA | Shape Australia | Buy - Morgans | Overnight Price $6.65 |
| Buy - Ord Minnett | Overnight Price $6.65 | ||
| SLC | Superloop | Overweight - Morgan Stanley | Overnight Price $3.33 |
| Buy - UBS | Overnight Price $3.33 | ||
| SSM | Service Stream | Overweight - Morgan Stanley | Overnight Price $2.61 |
| Buy - Ord Minnett | Overnight Price $2.61 | ||
| Buy - UBS | Overnight Price $2.61 | ||
| STO | Santos | Buy - Citi | Overnight Price $8.31 |
| Outperform - Macquarie | Overnight Price $8.31 | ||
| Overweight - Morgan Stanley | Overnight Price $8.31 | ||
| Hold - Ord Minnett | Overnight Price $8.31 | ||
| Buy - UBS | Overnight Price $8.31 | ||
| STP | Step One Clothing | Hold - Bell Potter | Overnight Price $0.16 |
| Hold - Morgans | Overnight Price $0.16 | ||
| SUL | Super Retail | Buy - Citi | Overnight Price $12.56 |
| Outperform - Macquarie | Overnight Price $12.56 | ||
| Neutral - UBS | Overnight Price $12.56 | ||
| SVR | Solvar | Accumulate - Morgans | Overnight Price $1.72 |
| SXE | Southern Cross Electrical Engineering | Buy - Bell Potter | Overnight Price $4.48 |
| TLC | Lottery Corp | Equal-weight - Morgan Stanley | Overnight Price $5.36 |
| Buy - Ord Minnett | Overnight Price $5.36 | ||
| Buy - UBS | Overnight Price $5.36 | ||
| TLX | Telix Pharmaceuticals | Buy - Bell Potter | Overnight Price $16.84 |
| TPW | Temple & Webster | Neutral - Citi | Overnight Price $4.15 |
| Downgrade to Equal-weight from Overweight - Morgan Stanley | Overnight Price $4.15 | ||
| TWE | Treasury Wine Estates | Buy - Citi | Overnight Price $5.60 |
| UNI | Universal Store | Buy - Citi | Overnight Price $7.05 |
| Buy - UBS | Overnight Price $7.05 | ||
| VCX | Vicinity Centres | Neutral - Citi | Overnight Price $2.53 |
| Neutral - Macquarie | Overnight Price $2.53 | ||
| VVA | Viva Leisure | Buy - Morgans | Overnight Price $1.53 |
| WGN | Wagners Holding Co | Buy - Morgans | Overnight Price $4.20 |
| WHC | Whitehaven Coal | Hold - Bell Potter | Overnight Price $7.55 |
| Overweight - Morgan Stanley | Overnight Price $7.55 | ||
| Buy - Ord Minnett | Overnight Price $7.55 | ||
| Neutral - UBS | Overnight Price $7.55 | ||
| ZIP | Zip Co | Buy - Citi | Overnight Price $2.58 |
RATING SUMMARY
| Rating | No. Of Recommendations |
| 1. Buy | 75 |
| 2. Accumulate | 6 |
| 3. Hold | 37 |
| 4. Reduce | 2 |
| 5. Sell | 4 |
Thursday 20 August 2026
Access Broker Call Report Archives here
Disclaimer:
The content of this information does in no way reflect the opinions of
FNArena, or of its journalists. In fact we don't have any opinion about
the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe
and comment on. By doing so we believe we provide intelligent investors
with a valuable tool that helps them in making up their own minds, reading
market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not
constitute an offer to sell or a solicitation to buy any security or other
financial instrument. FNArena employs very experienced journalists who
base their work on information believed to be reliable and accurate, though
no guarantee is given that the daily report is accurate or complete. Investors
should contact their personal adviser before making any investment decision.
Latest News
| 1 |
The Market In Numbers – 21 Nov 2026Nov 21 2026 - Australia |
| 2 |
ASX Winners And Losers Of Today – 20-11-26Nov 20 2026 - Daily Market Reports |
| 3 |
FNArena Corporate Results Monitor – 20-11-2026Nov 20 2026 - Australia |
| 4 |
Next Week At A Glance – 23-27 Nov 2026Nov 20 2026 - Weekly Reports |
| 5 |
Weekly Top Ten News Stories – 20 November 2026Nov 20 2026 - Weekly Reports |

